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LENGTH OF HOSPITAL STAY, DELIRIUM AND DISCHARGE STATUS 
OUTCOMES ASSOCIATED WITH ANTICHOLINERGIC DRUG USE IN ELDERLY 
HOSPITALIZED DEMENTIA PATIENTS 
By Kelly J. Gauthier, B.S. 
A Thesis submitted ill partial fulfillment of the requirements for the degree of Master of 
Science with a coi~centration in Phamiacotherapy at Virginia Commonwealth University 
Virginia Commonwealth University, 2006 
Major Director: Dr. Patricia W. Slattum, Pharm.D, Ph.D 
Assistant Professor and Geriatric Specialist 
Department of Pharmacy 
Problem: There are a significant proportion of patients taking acetylcholinesterase 
inhibitors (ChEi) for cognitive dysfunction also taking medications with anticholinergic 
(ACh) properties that may counteract their effects. As the number of ACh medications, 
burden, increases so does the likelihood of an adverse outcome. 
X 
Background: ACh medications are frequently used in the elderly population (Carnahan 
2004) even those with dementia or AD (Roe et al., 2002; Giron et al., 2001; Altavela 2003; 
Gill et al., 2005; Kogut et al., 2005). 
Methods: Hospitalized patients 2 65 years of age with dementia (AD, other dementias, or 
with inferred dementia based on ChEi or NMDA antagonist medication use) were studied 
using UHC clinical database. This document was created in Microsoft Word 2000. 
Results: Dementia patients on ChEi therapy were more likely to receive an ACh (chi- 
square 70.1, df=l, p<.0001) and had a significantly higher ACh burden (p=.0017) during 
hospitalization than those not on ChEi therapy. 
Conclusion: A person's age and mental health status along with their current drug 
regimen, such as ChEi therapy, need to be closely and carefully considered before deciding 
to use unnecessary ACh drugs in this population which can have detrimental effects. 
Chapter 1 Introduction 
I. Introduction 
Anticholinergic (ACh) medications are frequently used in the elderly population 
(Carnahan et al., 2004) even those with dementia or Alzheimer's Disease (AD) (Roe et al., 
2002; Giron et al., 2001; Altavela, 2003; Gill et al., 2005; Kogut et al., 2005). Surveys of 
administrative claims data from state Medicaid plans (Slatt~un et al., 2001 ; Carnaham et 
al., 2004), found that 13.5% and 35.4% respectively of patients receiving cholinesterase 
inhibitors (ChEi) were also receiving ACh drugs with significant central activity during a 
3-month period. 
The use of ChEi therapy has been associated with an increased risk of receiving an 
ACli drug (Gill et al., 2005). Some patients may be prescribed an ACh medication or a 
medication with ACh side effects to treat the side effects of ChEi therapy (Hashimoto et 
al., 2000) such as those used to treat urinary incontinence (Roe et al., 2002; Gill et al., 
2005). Even the use of incontinence medications to treat overactive bladder (OAB) in 
patients with AD, may have detrimental effects on mental status and behavior (Jewart 
2005). Other drugs such as tricyclic antidepressants (TCA), antipsychotics (AP), 
antispasmodics, antiparkinsons (benzotropine, trihexyphenidyl), antiarrhythmic 
(disopyramide) and older-generation antihistamines (diphenhydramine, 
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dimenhydrinate, chlorpheniramine) with known ACh activity are also frequently used in 
AD patients. Most ACh medication use can be deemed as an inappropriate medication for 
use in the elderly population (Agostini et al., 2001; Sloane et al., 2002; Fick et al., 2003; 
Carnahan et al., 2004). 
A number of studies have reported on the adverse effects associated with ACh 
drugs in general elderly populations. A few studies have found elderly to be at risk of 
cognitive impairment even at low serum ACh levels (Mulsant et al., 2003). Impairment of 
self-care capacity and cognition have been found to be associated with high serum ACh 
levels in dementia nursing home patients (Rovner et a1 1988). AD patients are at risk of 
additional cognitive impairment from ACh drug therapy (Thienhaus et al., 1990). 
The use of ACh medications or medications with ACh properties in community- 
dwelling elderly without dementia has been associated with lower cognitive performance 
(Lechevallier-Michel et al., 2004; Ancelin 2006). AD patients have shown clinically 
significant impairment of behavior and cognitive function (new learning and semantic 
knowledge) at lower doses of centrally acting ACh medications, such as scopolamine, 
compared to healthy, age-matched controls (Sunderland et al., 1987, 1988). 
ACh load or burden is when there is more than one ACh drug or drug with ACh 
properties co-administered. There are numerous studies which have shown ACh burden to 
be a strong predictor of cognitive impairment (Golinger et al., 1987; Rovner et al., 1988; 
Mach et a1.,1995; Mussi et al., 1999; Mulsant et al., 2003; Jeward et al., 2005; Chew et al., 
2005) and may be associated with excess disability in nursing home patients (Rovner et al., 
1988; Thienhaus et al., 1990). Tollefson et al., (1991), demonstrated that reducing ACh 
load or burden can cause significant changes in short term memory, delirium, and 
behavior. Even low ACh drug levels can cause mild but measurable cognitive impairment 
in elderly patients (Miller et al., 1988; Sands et a1 1997). 
Nishiyama et al., (1998), found a strong relationship between long-term exposure 
to ACh medications and cognitive deficits with older Parkinson's disease patients. There 
was also a significant association of chronic use of ACh medications (ie. 2 or more years) 
with increased AD-type pathology in the frontal cortex, even though patients in the study 
were not sufficiently symptomatic to warrant a diagnosis of dementia clinically (Perry et 
al., 2003). A study by Lu and Tune found that chronic exposure of ACh therapy may be 
associated with either detrimental effects on concomitant ChEi therapy or adverse effects 
on the clinical course of AD (Lu and Tune 2003). In their study, AD patients taking ChEi 
therapy and at least one ACh medication had similar decline in MMSE scores over two 
years as AD patients who were not receiving ChEi therapy. 
In hospital settings ACh medication exposure in older hospitalized patients has 
been associated with an increased risk of cognitive decline, behavioral disturbances and 
urinary catheter placement (Agostini et al., 2001; Han et al., 2001; Mulsant et al., 2004). 
A dose-response relationship has been demonstrated with diphenhydramine and adverse 
outcomes such as a significantly longer length of hospital stay and altered sleep-wake 
cycle (Agostini et al., 2001). Han et al., (2001), showed that ACh exposure, independent 
of initial severity of delirium or presence of delirium or other comorbid conditions, is 
associated with the severity of delirium symptoms in hospitalized elderly patients with 
diagnosed delirium. 
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The prevalence of delirium in older hospitalized patients is 10-25% and has 
significant hunian and economic burdens such as increased morbidity, a mortality of up to 
40%, significantly increased hospital lengths of stay, institutionalization, and functional 
disability (Thomas et al., 1988; Francis et al., 1990, 1992; Levkoff et al., 1992; Inouye et 
al., 1993; Murray et al., 1993; Rockwood 1993). According to Francis et al., (1990), 
approximately 40% of delirium cases in hospitalized elderly patients can be attributed to 
medications. 
11. Study Objectives 
The specific aims of this study are: 
To determine the prevalence of ACh use in hospitalized elderly patients with 
dementia. 
To determine the prevalence of ACh use in hospitalized elderly patients with 
dementia on ChEi. 
To compare the prevalence of ACh use between hospitalized elderly patients wit11 
dementia on and not on ChEi therapy. 
To compare ACh burden between hospitalized elderly patients with dementia on 
and not on ChEi therapy. 
To characterize prescribing patterns of ACh medications in the hospitalized elderly, 
particularly those with dementia with or without ChEi therapy 
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To compare the prescribing patterns of urinary antispasmodics, GI antispasmodics, 
and ACh antispychotics between hospitalized elderly patients with dementia on and 
not on ChEi therapy. 
To evaluate and compare the impact of ACh medication use in hospitalized 
dementia patients on length of hospital stay, discharge status, and having delirium 
while in the hospital. 
To evaluate and compare the impact of ACh burden in hospitalized dementia 
patients on length of hospital stay (LOS), discharge status, and having delirium 
while in the hospital. 
111. Purpose and Significance 
A. Purpose 
The mainstay of AD treatment is through enhancing cholinergic neurotransmission 
with ChEi. Cholinesterase inhibitor therapy is associated with significant cost for AD 
patients. Giving other medications that block or counteract the potential benefits of this 
therapy make those costs an unnecessary burden on the family and the health care system 
as a whole. 
The hypothesis guiding this research is that a significant proportion of patients 
taking ChEi for cognitive dysfunction are taking medications with ACh properties that 
may counteract their effects. As the number of ACh medications or ACh burden 
increases, so does the likelihood of an adverse outcome. 
B. Significance 
No studies have reported on the ACh effects in hospitalized dementia patients. No 
studies have examined whether the use of ChEi therapy in hospitalized dementia patients 
taking ACh medication will have any effect on the adverse events associated with the use 
of ACh medications. To date, there has been one study conducted in one hospital which 
evaluated the use of one ACh drug, diphenhydramine, in hospitalized elderly patients. 
This study will look at a clinical database with data on the use of numerous ACh 
medications from 42 academic health centers from across the country. The descriptive 
data obtained from this study will provide valuable information on the prevalence of 
concomitant use of ACh and ChEi therapies. This study will provide information on the 
adverse events associated with ACh use in dementia patients. It will also attempt to 
provide some insight on the differences of ACh prescribing patterns between dementia 
patients taking and not taking ChEi therapy. 
Chapter 2 Literature Review 
I. Alzheimer's Disease 
A MedlineIPubmed search (time frame: up to January 2006) was performed to find 
articles on the course, pathology, and prevalence of AD, the role of cholinesterase and 
acetylcholine in AD, and the treatment of AD. Search terms used were: Alzheimer's 
disease, acetylcholine and Alzheimer's disease, cholinesterase and Alzheimer's disease, 
dementia, cholinergic receptor, muscarinic receptor, Alzheimer's disease treatment, and 
cholinesterase inhibitors and Alzheimer's disease. 
AD is a progressive neurodegenerative disorder and eventually leads to death. It 
is the most common cause of dementia. A diagnosis of AD is not affirmative until death, 
upon autopsy. Prevalence studies suggested that in 2000, the number of persons with 
Alzheimer's disease in the United States was 4.5 million (Herbert et al., 2003). The 
percentage of persons with Alzheimer's disease increases by a factor of two with 
approximately every five years of age, meaning that 1 percent of 60-year-olds and about 30 
percent of 85-year-olds have the disease (Jorm 1991). Without advances in therapy, the 
number of symptomatic cases in the United States is predicted to rise to 13.2 million by 
2050 (Herbert et al., 2003). The cost of caring for patients with Alzheimer's disease is 
extraordinary, with annual expenditures totaling $83.9 billion (in 1996 U.S. dollars) 
(Wimo and Winbald 2001). 
There are three consistent neuropathological hallmarks in the pathology of AD: 
amyloid-rich senile plaques, neurofibrillary tangles, and neuronal degeneration. There are 
many hypotheses on the pathology of AD and what causes these hallmarks. One 
hypothesis is that the symptoms of AD result fiom the accumulation of beta-amyloid 
peptide. Other hypotheses associate AD pathology with the hyperphosphorylation of Tau 
protein, heavy metals, vascular factors, viral infections, and the loss of cholinergic 
neurons. 
A. The cholinergic hypothesis 
The cholinergic hypothesis correlates the loss of acetylcholine activity, due to death 
of neurons, with the severity of AD (Bartus et al., 1982). Compared to individuals without 
AD, patients with AD demonstrate significant reductions in cholinergic activity in areas of 
the brain (cortical and subcortical) important in the processes of memory and learning. 
The changes in cholinergic activity are due to reductions in choline acetyltransferase 
activity and number of cholinergic neurons in late AD, and selective loss of nicotinic 
receptor subtypes in the hippocampus and cortex (Bartus et al., 1982; Whitehouse et al., 
1982; Guan et al., 2000). 
These changes in the central cholinergic nervous system, both age- and disease- 
related, contribute to the functional decline, memory impairment, behavioral disturbances, 
and worsening quality of life seen in AD. It has been demonstrated by numerous studies 
that the extent of cholinergic loss in AD is correlated with the severity of cognitive 
dysfunction and disease duration, as well as with the density of senile plaques of beta- 
amyloid protein and intracellular neurofibrillary tangles (Perry et a1 1978; Bierer et al., 
1995; Bowen et a1 1982; Cumniings and Cotman 1995; Everitt and Robbins 1997). 
B. Treatment of AD 
Because of the functional outcomes of AD (functional decline, memory 
impairment, behavioral disturbances, and overall worsening quality of life) and the fact 
that there has been death of neurons, leads us to how AD is treated. In AD treatment only 
the the symptoms are treated and not the disease itself. 
The first treatment approach and currently the mainstay in mild to moderate AD is 
the enhancement of cholinergic transmission with ChEi. ChEi enhances cholinergic 
neurotransmission through inhibition of cholinesterase, the enzyme responsible for 
hydrolyzing acetylcholine, in the central nervous system and therefore allowing 
acetylcholine to remain in the synaptic cleft longer (Hogan and Patterson, 2002). 
Maximizing cholinergic function may help patients maintain their ability to perform 
activities of daily living (ADLs), temporarily slow cognitive decline/functional 
deterioration, reduce emergence of behavioral disturbances, reduce caregiver burden and 
defer placement in long term care (LTC) facilities (Cummings, 2004). Studies of ChEi 
therapy show that there is a four to seven point improvement on the AD Assessment Scale- 
cognitive proportion (ADAS-cog), a psychometric test, commonly used to establish 
efficacy with respect to cognitive function. 
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Maximizing the cholinergic system, also causes the common side effects of nausea, 
diarrhea, and urinary incontinence through increasing activity at peripheral muscarinic 
receptors. The actual incidence of urinary incontinence and how often ChEi therapy 
worsens it are unknown. 
A newer approach in the treatment of AD is memantine (Nemenda @), a N-methyl- 
D-aspartate antagonist approved for treatment of moderate to severe AD. Its benefits are 
either through interfering with the glutamatergic excitotoxicity caused by beta-amyloid 
peptide or its effects of symptomatic improvement on the hippocampal neurons (Parsons et 
al., 1999). In clinical trials there were no clinically relevant differences between moderate 
to severe AD patients in the memantine and placebo groups in terms of adverse events, 
laboratory findings, electrocardiographic studies, or vital signs. When memantine was 
administered to patients with moderate-to-severe Alzheimer's disease who were receiving 
stable doses of a ChEi, cognitive improvement was seen as a reduced decline in ADLs and 
a reduced frequency of new behavioral symptoms as compared with those receiving 
placebo (Tariot et al., 2004). The magnitude of the improvements in patients in these trials 
is modest, with improvement or temporary stabilization observed in daily function or 
behavior. 
11. Anticholinergics 
A MedlineJPubmed search (time franie: upto January 2006) was performed to find 
articles on ACh and their effects on the geriatric population (2 65), both demented and 
non-demented, and their use in geriatrics. Search terms used were: anticholinergic, 
anticholinergic and Alzheimer's disease, anticholinergic and cognitive function, 
anticholinergic and dementia, anticholinergic and memory, anticholinergic and elderly, 
anticholinergic and geriatric, anticholinergic and older persons, anticholinergic and side 
effects, anticholinergic and urinary incontinence, treatment of overactive bladder, and 
prevalence of anticholinergic and elderly. 
ACh bind to muscarinic receptors to block acetylcholine actions and hence 
decrease cholinergic neurotransmission. ACh medications are often used in the treatment 
of movement disorders like Parkinson's Disease (benztropine, trihexyphenidyl), urinary 
incontinence (tolterodine, oxybutynin, and the newer agents), dizziness (meclizine), and 
insomnia (diphenhydramine). The common side effects of ACh are dry mouth, 
disorientation, confusion, delirium, memory impairment, sedation, blurred vision, changes 
in heart rate (bradycardia or tachycardia), urinary retention, and constipation. 
A. Muscarinic receptors 
There are two types of cholinergic (ACh) receptor systems: muscarinic and 
nicotinic. There are at least five subtypes of muscarinic receptors (MI, M2, M3, M4, and 
M5) which can be found distributed throughout the brain and (MI, M2, M3, and M4) in 
different areas of the body. Areas of the body where the different receptor subtypes can 
be found are listed in Table 1 on the following page. 
Table 1. Locations of muscarinic receptor subtypes 
 
M 1 brain (cerebral cortex, hippocampus, & neostriatum), bladder, 
salivary glands, sympathetic ganglia 
I M2 brain (throughout), bladder, eyes, heart, smooth muscle I 
I M3 brain, eyes, smooth muscle, salivary gland, bladder I 
M4 brain (neostriatum, cortex, hippocampus), bladder, salivary glands 
MS brain (hippocampus & projection neurons of substantia nigra, pars 
cornpacta, & ventral tegmental area), eyes (ciliary muscles) 
All muscarinic receptor subtypes (MI-M4) are present in various regions of the 
human brain. Of the receptor subtypes, MI is the most abundant in the cerebral cortex and 
hippocampus, M2 are located throughout the brain, and Mj are located in low levels 
throughout the brain. The muscarinic receptors of the brain are involved in several 
processes including memory, learning, control of movement, nociception, and regulation 
of circadian rhythm. 
The cholinergic system exerts a major influence on the cognitive process, in 
particular memory via MI cholinergic receptors as demonstrated through studies using 
genetically modified (knockout) mice. Inhibition of the MI subtype in the brain is known 
to disrupt cognitive functions such as learning and memory (Kay and Granville 2005). 
Recent evidence suggests a role for M2 (Teaktong et al., 2005) receptors in mediating 
cognitive function. Similar studies with knockout mice lacking M2 receptors show 
significant deficits in behavioral tasks requiring working memory and dysregulation of 
cholinergic function in the hippocampus, which are associated with cognitive deficits 
(Lazaris et al., 2003). Other genetic studies have implicated a role for striatal M4 
autoreceptors in the regulation of acetylcholine levels (Zhang W et al., 2002). 
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Approximately two-thirds of the n~uscarinic receptors of the bladder are M2 and 
one-third M3. Both M2 and M3 muscarinic receptors facilitate contraction of the bladder, 
but the M3 subtype is principally responsible for detrusor muscle contraction. 
B. ACh and their use in urinary incontinence 
New onset or worsening incontinence is commonly seen as part of the natural 
history of dementia (Skelly and Flint 1995) and are highly prevalent and likely to occur 
simultaneously in the elderly. Urinary incontinence occurs in approximately 33% of 
women and 15-20% of men over the age of 65,50% of frail elderly or those over the age of 
85 who have multiple comorbidities and at least 60-80% of residents of nursing homes or 
skilled facilities receiving around the clock care (Jewart et al., 2005). Urinary incontinence 
is not only common in fiail older adults, but has been associated with significant 
morbidity, specifically premature nursing home placement (Thakar et al., 2000). 
ACh agents such as oxybutynin, tolterodine, trospium, darifenacin, and solifenacin 
(Table 2) are frequently used to treat overactive bladder in the elderly population and in 
particular those with AD or Parkinson's disease (PD). 
Table 2. ACh agents available for the treatment of OAB 
Drug Formulation Dosing chemical structure selectivity 
Tolterodine (Detrol) IR 1,2 mg BID nonlipophilic, tertiary amine nonselective 
ER 2,4mg QD 
Oxybutynin (Ditropan) IR 5mg BTID lipophilic, tertiary amine M3, MI >>M2 
ER 5, 10, 15,20mg QD 
skin patch 3.4mgId every 3-4days 
Trospium (Sanctura) IR 20mg BID quaternary amine nonselective 
(at least one hr before food) 
Darifenacin (Enablex) CR 7.5, 15mg QD tertiary amine M3 
Solifenacin (Vesicare) CR 5,lOmg QD tertiary amine M3 
IR: immediate release; ER: extended release; CR: controlled release; QD: once daily; BID: twice daily; BTID: 2-3 times daily 
ACh agents currently used in the treatment of OAB have the potential to bind to 
muscarinic receptors throughout the body, thereby mediating a variety of related adverse 
events. There is growing evidence from different sources suggesting that treatment of 
OAB with nonselective muscarinic antagonists may result in memory dysfunction (Tsao 
and Heilman, 2003; Womack and Heilman, 2003), confusion and disorientation (Edwards 
and O'Connor 2002) in the elderly population. 
There are other factors that can affect a drugs capability to exert its effects on the 
CNS by crossing the blood brain barrier (BBB). Factors that favor a medication's passive 
penetration of the BBB include lipophilicity, a neutral charge, and a smaller, less bulky 
molecular size. Trospiwn is the only quaternary amine used in the treatment of OAB. The 
quaternary amine gives the trospium molecule a positive charge making it highly polar and 
decreased lipophilicity and therefore is less likely to cross the BBB than the tertiary 
mines. Its nonspecific effects are mainly seen in the periphery. 
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Even though there are urinary incontinence medications that are receptor specific or 
have a permanent charge to reduce its crossing of the BBB, there are still a number of 
conditions that can increase the BBB permeability and therefore allowing drugs to cross 
the blood brain barrier that would not have normally. These include being elderly (2 65), 
use of certain medications, comorbid diseases and stress (Pakulski et al., 2000; Star et al., 
2003; Abdel-Rahman et al., 2004). The integrity of the BBB in those 65 years old and 
older is unknown. Quaternary arnines have been shown to cross an intact BBB in animals 
exposed to stress (Abdel-Rahman et al., 2004). There are also many comorbid conditions 
that are common in older people that may make them more susceptible to cognitive 
impairment and exaggerate the ACh drug effects on cognitive function (Doraiswamy et al., 
2002). Such conditions are type I1 diabetes mellitus, coronary artery bypass graft surgery, 
cerebrovascular disease, Parkinson's disease, and AD and related dementias. In other 
words, all ACh medications, regardless of their physiochemical properties, should be 
considered to have the potential to cross the BBB. 
C. Concomitant use of ACh and ChEi 
There have been numerous studies that have looked at the prevalence of the 
concomitant use of ACh and ChEi drugs. These studies are summarized in Table 3. 
Studies by Carnahan and Roe found that approximately 35.4% of those on ChEi therapy 
were also receiving at least one ACh, defined as ACh agents with clinically relevant ACh 
properties from the Beer's criteria (Carnahan et al., 2004; Roe et al., 2002). Surveys of 
administrative claims data from Medicaid plans found that 13.5-35% of patients receiving 
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ChEi therapy were also receiving ACh drugs with significant central activity (Slattum et 
al., 2001; Carnahan et al., 2004). Carnahan et al., (2004), was from January 1997 to 
Febuary 2000. The use of ChEi therapy has been associated with an increased risk of 
receiving an ACh drug to manage urinary incontinence (Gill et al., 2005). 
Table 3. Published studies of the prevalence of concurrent ChEi & ACh 
Authors, yr Patient population Study Design Conclusionlfindings 
Roe CM, n=836 (418 on each member from ChEi group was rn older adults wlprobable dementia were 
Anderson MJ, donepezil; 418 not on matched with a member from the more likely to use ACh. 
Spivack B. 2002 donepezil therapy) comparison group In ChEi group, those receiving ACh: 33% 
used 1 1  ACh med; 
community-based used 3-12 months of pharmacy claims rn community-based, commercially insured, 
adults (>65) data older adults wlprobable dementia are 
more likely to take ACh (TCAs,, 
antipsychotics, UI drugs) than matched 
controls. 
Camham RM, n=557 pharmacy claim for ChEi & ACh over rn 35% of pts receiving ChEi also received 
Lund BC, et al., Iowa medicaid a 180d period, counted #ACh received - >1 ACh; 
2004 beneficiaries (150) and timing (before or after ChEi o those receiving ACh: nearly 75% were 
initiation) considered as inappropriate for use in 
elderly 
of which 22% were deemed 
inappropriate under any 
circumstance. 
ACh prescibing upon ChEi therapy 
inception: cimetidine, ranitidine, 
atropine, dicyclomine, hyoscyamine, 
oxybutynin, & tolterodine 
Gill SS, Mamdani n= 44884 -used administrative health care There was a significant increase in 
M, et al., 2005 study of older adults; databases of Ontario, Canada receiving an ACh after initiation of ChEi 
(n=20491) wl -use of oxybutynin, tolterodine, or therapy; risk was same among the LTC 
dementia who flavoxate initiation of oxybutynin, and community-dwelling settings 
received ChEi tolterodine, or flavoxate, for treatment rn use of ChEi was associated with an 
therapy of urinary incontinence after ChEi increased risk of receiving an ACh drug to 
(n=24393) who didn't therapy is started manage urinary incontinence 
Kogut SJ, El- n=1183 Use of developed list of drugs that can approximately 60% of patients taking 
Maouche D, (145) residing in the impair cognition through review of ChEi also received a drug that can impair 
Abughosh SM. community or LTC similar lists used by other researches cognition 
2005 facility dispensed a 
ChEi 
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There are many reasons cited in the literature as to why ACh and ChEi should not 
be used together. The American Psychiatric Association and the American Academy of 
Neurology both have guidelines that reinforce the warning of the high risk of adverse 
effects of ACh drugs given to patients with dementia. 
Chronic exposure to ACh medications can adversely affect the course of AD (Lu 
and Tune 2003). In a two year retrospective study in 69 patients diagnosed with probable 
AD and receiving donepezil, patients were divided into two groups based on the number of 
ACh medications they were concomitantly taking. Sixteen subjects received at least one 
ACh medication and 53 were not taking any ACh drugs concomitantly. Patients took an 
annual Mini Mental State Examination (MMSE) and had blood drawn for the serum 
anticholinergic activity (SAA) radioreceptor assay. They found that those patients that 
were receiving ACh drugs showed a significantly greater decline, an average decline of 7 
points over 2 years, in MMSE scores than those who were not taking ACh drugs, average 
decline of 3 points over 2 years. Those that were taking ACh conconlitantly experienced 
similar declines in their MMSE scores as patients who do not take ChEi therapy (average 
decline of 3.5 points per year) (Burns et al., 1991). The findings suggest that concomitant 
treatment with ACh drugs may be associated with significant deleterious effects on ChEi 
therapy or that chronic exposure to ACh may have adverse effects on the clinical course of 
AD. 
Studies by Sunderland et a1 and Agnoli et al., have shown that the addition of 
medications with ACh properties may diminish any potential benefits from ChEi and 
possibly exacerbate cognitive decline in AD patients (Sunderland et al., 1987, 1988; 
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Agnoli et al., 1983). AD patients are at risk of additional impairment from ACh drug 
therapy (Thienhaus et al., 1990). In an observational study in geropsychiatric inpatients, 
ten with probable AD and 18 without significant impairment, participants were subject to a 
battery of cognitive tests and had their SAA measured. Non-demented subjects were 
significantly less vulnerable to the cognitive effects of ACh drugs than were the demented 
patients. The implication being that ACh drugs may be associated with excess disability in 
geriatric inpatients. There have also been case reports of delirium with oxybutynin and 
tolterodine in patients that were also concomitantly taking ChEi therapy (Edwards et al., 
2002) 
D. ACh and Delirium 
ACh medications are a well-known cause of delirium most likely due to a direct 
reduction in central cholinergic activity. N~mierous challenge studies have found 
impairments in various aspects of cognitive function after administering standard 
therapeutic doses of ACh medications to normal healthy adults (Mulsant et al., 2003; 
Rovner et a1 1988; Katz et al., 1998; Lechevallier-Michel et al., 2004; Ancelin 2006). 
The results of the Sunderland et al., study suggest that dementia may modify the 
ACh-deliriuni relationship. Their study, patients with dementia showed significant 
cognitive decline at doses of ACh medications at which their non-demented controls did 
not (Sunderland et al., 1987). 
Cholinergic antagonistic binding at these muscarinic receptors can further impact 
dementia and cognitive deficits in patients with dementia of Lewy bodies (DLB), which 
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accounts for 15-25% of dementia in the elderly (Teaktong et al., 2005), and those with 
Alzheimer's disease (AD). Therefore current data suggests that cognitive impairment, in 
particular memory dysfunction, could result fiom antagonism of MI and to some extent M2 
and M4 receptors in the CNS. Thus, older patients with existing cognitive impairment, 
especially those with early-stage dementia, age-associated memory impairment, or mild 
cognitive impairment may be especially vulnerable to these cognitive side effects. 
Numerous studies have noted an association between medications with ACh 
properties and delirium. Table 4 summarizes studies on ACh drug use and their 
association with delirium. Even though this syndrome has long been recognized, the full 
extent of its nature is not yet fully understood. The ACh effects of many drugs and their 
metabolites are unknown and since most elderly patients take a number of medications, it 
is difficult to discern what their ACh burden is, thus there needs to be a method for 
measuring or assessing one's ACh burden. 
Table 4. Published studies: ACh and delirium 
Definition o f  Ach drug 
Authors, yr Patient population or  burden & delirium ConclusioniFindings 
meaurement 
n=29 
Tune LE, et al., 1981 cardiac surgery pts 10 delirious pts 
(29-75 yo) 19 control pts 
delirium was significantly associated with SAA. 
higher SAA was associated with lower MMSE 
Golinger RC, Peet T, n=16 Plasma AA & drug-risk Plasma AA was signifiicantly higher in the 
Tune LE. 1987 surgical ICU pts. number delirious pts (ave age=60) than in the pts wlo 
(29-76 yo) delirium (ave age=57). 
Francis et al., 1990 n=229 MMSE, DSM-111 and ACh drug use was not associated with delirium. 
community-dwelling noted if pt had taken an 
elders admitted to ACh 
medical ward (> 70) 
Schor et al., 1992 n=29 1 DSM-111 and counted Delirium not significantly associated with ACh 
general and medical ward number of doses received drug use 
pts (1 65) 
(Table 4 continued from pg 19) 
Definition of Ach drug 
Authors, yr Patient population or burden & delirium Conclusion/Findings 
meaurement 
Tune LE, et al., 1993 n=25 SAA & DSM-I11 Significant relationship between SAA and 
surgical ICU pts (29-74 delirium. 
YO) 
Marcantonio et al., n=91 MMSE, CAM, and Delirium not significantly associated with ACh 
1994 surgical pts counted number of doses drug use 
received 
Mach JR, Dysken 
MW, et al., 1995 
n=12, 
male delirious & non- 
delirious pts (> 60) 
case-control study.& 
with-in subjects repeated- 
measures in recovered 
delirious pts 
SAA mean SAA was significantly elevated in delirious 
group vs non-delirious group 
Flacker JM, et al., n=67 medical ward pts 2 20 delirious patients vs 47 SAA was associated with delirium in a 1 1998 75 yo non-delirious patients multivariate analysis I 
Flacker JM, Lipsitz n=22 NH residents 8 delirious pts SAA appears to be elevated during illness, and 
LA. 1999 14 non-delirious pts declines following recovery from illness and not 
associated with delirium. 
Mussi C, Ferrari R, et n=61; elderly pts (1 66 divided into 2 groups high levels of SAA were significantly correlated 
al., 1999 yo) admitted to hospital based on presence (n=12) with delirium 
or absence (n=49) of 
delirium 
yo= years of age; pts= patients; AA= ACh activity; BZ= benzodiazepines 
111. Delirium and Adverse Outcomes 
A MedlineIPubmed search (time frame: upto January 2006) was conducted to find 
articles on delirium and its effects on the geriatric population (2 65), and the frequency of 
delirium occurrence and adverse outcomes associated with developing delirium during 
hospitalization in the elderly. Search terms used were: delirium and geriatric, delirium and 
elderly, delirium and older persons, delirium and hospitalization, delirium and morbidity, 
and delirium and mortality. 
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Delirium is defined as an acute disorder of attention and cognition and occurs in 
14-56% of hospitalized elderly patients (Rosin and Boyd 1966; Chisholm et al., 1982; 
Gillick et al., 1982; Levkoff et al., 1992; Inouye et al., 1993). Delirium has been 
associated with several adverse outcomes such as increased rates of morbidity, mortality 
and institutional placement, and with loiiger, costlier hospitalizations (Weddington 1982; 
Thomas et al., 1988; Rockwood 1990; Levkoff 1992). Mortality rates of 12-76% have 
been reported (Weddington 1982; Lagoe RJ 1986; Thomas et al., 1988). 
In a prospective study by Francis et al.,, participants in the study were 70 years or 
older, admitted directly to the medical ward from the community and underwent evaluation 
within in 48 hours of admission. The evaluation included an interview, chart review, 
MMSE, an assessment of ADL, and Blessed's Dementia Rating Scale. Patients were 
followed up on six months after discharge by phone. Patients who developed delirium 
stayed an average of 12.1 days longer in the hospital than those who did not. They also 
were 8% more likely to die or 16% more likely to be institutionalized compared to those 
who did not develop delirium (Francis et al., 1990). 
Medical comorbidity and predisposing, as well as precipitating, factors are 
important to consider in the management of delirium. Major risk factors for delirium 
include advanced age, cognitive impairment, and chronic medical illness (Williams et al., 
1985; Foreman 1989; Francis et al., 1990; Schor et al., 1992). 
Schor et al., calculated incidence of delirium and risk factors for delirium in elderly 
hospitalized patients. Patients in their study were 65 years or older admitted from either a 
rehabilitation center for the aged or the community. Diagnosis for delirium was based on 
Diagnostic and Statistical Manual of Mental Disorders, third edition (DSM-111). In the 
Schor et al., study nearly one third of the 325 patients who participated developed 
delirium. Patients who developed delirium had a mean length of stay of 18.8 days vs 13 
days in those who did not develop delirium (Schor et al., 1992). Almost 50% had met the 
DSM-I11 criteria for delirium by day 3 and 91% by day 7 of their hospital stay. Admission 
risk factors found to be strongly predictive of delirium were age greater than 80, prior 
cognitive impairment, fracture on admission, and institutionalization prior to admission. 
Levkoff et al., evaluated the occurrence and persistence of delirium in 325 elderly 
patients admitted to a teaching hospital from either the community or LTC facility. On 
admission approximately 1 1% met DSM-I11 criteria for delirium and of the remaining 
patients nearly one third developed new onset delirium during their hospitalization. Risk 
factors identified in this study for the development of delirium were preexisting cognitive 
impairment and advanced age. Increased risk of developing delirium was seen in those 
admitted from the comnlunity and not from institutions. They also found delirium to be 
associated with prolonged hospital stay and an increased risk of institutional placement 
among the community dwelling but not an increased risk of mortality (Levkoff et a1 1992). 
IV. Assessing ACh burden 
ACh burden refers to the cumulative effect of taking multiple drugs with ACh 
activity. A MedlineIPubmed search (time frame: upto March 2006) was conducted to find 
all articles that used ACh burden as a predictor of delirium in elderly individuals to see 
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how ACh burden was calculated and defined. Search terms used were: anticholinergic 
burden, serum anticholinergic activity, anticholinergic activity, and anticholinergic effects. 
There are four general methods for measuring ACh burden they are: measurement 
of total SAA resulting from drugs, metabolites, and patient physiology; ACh drug lists 
combined with clinical judgement; measurement of individual drug-related ACh activity; 
and measurement of individual muscarinic receptor affinity in vitro. Sometimes these 
methods are combined. 
A. Serum Anticholinergic Activity 
One commonly used method for measuring ACh burden is by measuring the SAA. 
SAA was first described by Tune and Coyle (1980) to quantify the ACh burden of drug 
exposure. The assay is performed by incubating a small amount of sample solution of an 
ACh in a phosphate buffer containing [3~]quinuclidinyl benzilate (QNB), a potent 
muscarinic antagonist, and a suspension of rat striatal membranes, which are rich in 
muscarinic receptors. The ACh substances in the sample competitively inhibit the binding 
of the radioactively labeled QNB to the receptors to a degree determined by their 
concentrations and affinity for these receptors. In other words, it measures the binding 
affinity, ACh potency (the higher the binding affinity the greater the ACh potency) of ACh 
drugs and also of non-ACh drugs that exhibit ACh-like properties such as TCA. The 
binding affinity is usually measured in atropine equivalents so that comparisons may be 
made across different drugs. SAA has been used in many studies and has been found to be 
associated with mental status changes in a number of clinical settings and patient 
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populations. Table 5 summarizes all of the published studies reviewed on the relationship 
of SAA and cognition. 
SAA was measured in postoperative cardiac patients from 29-75 years of age (Tune 
et al., 1981). Elevated levels were significantly associated with an increased risk of 
delirium and reductions in scores on the MMSE correlated with SAA levels (p < .001). 
Another study (Golinger et al., 1987) looked at surgical patients in the ICU ranging from 
25-76 years of age and found that mean SAA was significantly greater in delirious patients 
than in nondelirious patients (p < .05). 
Flacker et al., 1998, found an association between higher SAA levels with delirium 
in 67 medical inpatients over 75 years of age (p = .006). The patients SAA levels were put 
into quintiles, 1 being the lowest and 5 the highest levels. The prevalence of delirium 
increased steadily from 7.7% in the first quintile to 6 1.5% in the fifth quintile. 
In another study by Flacker et al., 1999, SAA, MMSE, and the delirium symptom 
interview were measured in 22 nursing home residents during a febrile illness and then 
again at one-month follow-up. Those in the delirious group had higher Cognitive 
Performance Scale scores, indicating more impairment, than those that were not delirious 
(p < .01). SAA in this study was not significantly different between the groups at baseline 
or at follow-up. 
In a study for risk factors for delirium in patients admitted to a geriatric medical 
ward, Mussi et al., 1999 found that elevated SAA levels were independently associated 
with the presence of delirium (p < .004) along with antipsychotic use (p < .002) and 
benzodiazepine use (p < .005). 
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Rovner et al., 1988, studied the relationship between SAA levels and self-care 
capacity in 22 demented nursing home patients. Those patients that had SAA levels above 
the median SAA displayed significantly greater impairment in self care than did patients 
below the median (p = .03). 
Miller et al., 1988, evaluated cognitive function in relation to SAA in presurgical 
patients over the age of 59 and showed that even low SAA levels can significantly impair 
patient's performance on cognitive testing. Cerebrospinal fluid ACh activity was 
measured in nine patients who received spinal anesthesia and was found to be significantly 
correlated with SAA (p<.05). 
Thienhaus et al., 1990, studied SAA effects in geropsychiatric inpatients with 
probable AD compared to patients without cognitive impairment. In the probable AD 
patients there was a significant increase in SAA with the implemented drug therapy and 
SAA was significantly associated with worsening on a number of cognitive measurement 
scales. This same finding was not found in the patients without cognitive impairment 
suggesting that demented patients may be more susceptible to the detrimental cognitive 
effects of ACh medications than nondemented patients. 
Table 5. Published Studies: Relationship between SAA and cognition 
Authors, yr Patient Population Study Design Outcome Measure@) Conclusion/ Findings 
Tune LE, et al., n=29 10 delirious pts SAA -delirium was significantly 
1981 cardiac surgery pts 19 control pts associated with SAA. 
(29-75 yo) -higher SAA was associated with 
lower MMSE 
Mondimore FM et post-ECT pts pts treated with SAA and MMSE higher SAA levels associated with 
al., 1983 (17-76 yo) atropine decrease in MMSE 
(Table 5 continued from page 25) 
Authors, yr 
Golinger RC, Peet 
T, Tune LE. 1987 
Patient Population Study Design 
n=16 9 delirious pts 
Outcome Measure(s) 




plasma ACh significantly higher 
in the delirious pts than in the pts 
without delirium 
surgical ICU pts 16 non-delirious pts 
(29-76 YO) 
Miller PS, 
Richardson JS, et 
al., 1988 
n=36 Scopolamine (n=14) 
presurgical elderly placebo (n=16) 
pts (>59 yo) 
SAA & CSF ACh levels; 
mental status battery test 
(RAVL). 
low ACh drug levels can cause 
mild but measurable cognitive 
impairment in elderly pts. 
Rovner BW, 
David A, et al., 
1988 
n=22 All residents with 
demented NH pts cognitive impairment 
MMSE; SAA -SAA levels were related to 
cognition & capacity for self- 
care. 
-high ACh levels associated with 
greater impairment in self-care 
capacity than pts with low levels 
Thienhaus, Allen, n=28 probable AD (n=10) 
et al., 1989 geropsychiatric compared to pts 
inpatients without significant 
cognitive impairment 
(n=18) 
MMSE, Digit Retention 
Span, word recognition, 
category retrieval, Self- 
rated Memory Scale 
(SRM); SAA 
-non-demented subjects were 
significantly less vulnerable to 
cognitive effects of ACh than 
demented pts 
-cognitive performance decreased 
as ACh load increased 
Tollefson GD, 
Montague-Couse 
J, Lancaster SP. 
1991 
Tune LE, et al., 
1993 
n=34; NH residents 
1 6 5 ~ 0  
receiving 21 ACh 
medicine 
15 intervention pts 
19 control pts 
SAA; battery of 
Psychometric testing 
reducing ACh load gave a 
lowered SAA and was 
significantly related to improved 
cognitive performance 
n=25 
surgical ICU pts 
(29-74 yo) 
9 delirious pts 
16 control pts 
SAA & DSM-111 Significant relationship between 
SAA and delirium. 
Mach JR, Dysken 
MW, et al., 1995 
n=12 
> 60 yo male 
-




mean age of 69 
11 delirious pts 
11 control pts 
SAA Resolution of delirium was 
associated with decrease in SAA 
Nebes RD, et al., 
1997 
17 with undetectable 
SAA; 19 with 
detectable SAA 
20 delirious patients vs 
47 non-delirious 
patients 
8 delirious pts 
14 non-delirious pts 
SAA detectable SAA was associated 
with lower cognitive performance 
Flacker JM, et al., 
1998 
SAA & Delirium 
symptom interview 
SAA was associated with delirium 
in a multivariate analysis 
n=67 
medical ward pts 
( r 75) 
Flacker JM, 




scale (CPS); SAA 
SAA appears to be elevated 
during illness, and declines 
following recovery from illness 
and not associated with delirium. 
Mussi C, Ferrari n=61; elderly pts divided into 2 groups 
R, et al., 1999 ( 1  66 yo) admitted based on presence 
to hospital (n=12) or absence 
(n=49) of delirium 
CAM for presence of 
delirium; SAA 
high levels of SAA were 
significantly correlated 
wldelirium, 
Mulsant BH, n=201; community 21 pts with 
Pollock BG, et al., study based on age undetectable SAA 
2003 & sex ( 1  65) 159 pts with low SAA 
21 pts with high SAA 
cognitive performance: 
MMSE; SAA 
2 strongest predictors of cognitive 
imprt: MMSE & ACh load. Ach 
load was a very strong predictor 
in degree of cognitive 
impairment, even low SAA was 
associated with cognitive 
impairment. 
Chew ML, n=26; Baseline SAA 
Mulsant BH, et al., geropsychiatric 
2005 inpts treated for 
behavioral disturbx 
assocd wldementia 
pts: patients; yo: years of age; SAA= serum ACh activity; d/o=disorder 
cognition: MMSE & 
severe impairment 
battery; SAA 
in patients with moderate-severe 
dementia- higher SAA assocd 
with lower cognitive performance 
The advantage to this method is that it has been shown in numerous studies to be 
related to cognitive impairment or improvement. Limitations to this method of measuring 
ACh burden are that it is an invasive procedure which requires blood samples to be drawn. 
Also, it is not a commercially available test and it doesn't provide a basis on which to rank 
the contribution of ACh activity from individual drugs and therefore limits its use in 
clinical practice and research studies. 
B. ACh drug lists combined with clinical judgment 
There are several subjective and objective published developed lists (Flacker et al., 
1998; Mintzer 2000; Tune 2001; Miller 2002; Roe et al., 2002; Mulsant et al., 2003; Mann 
et al., 2003; Defilippi 2003; Scheife et al., 2005) available that can be used in combination 
with clinical experiences, to rate the ACh activity of the drug in question. Table 6 
summarizes all of the published lists. 
The subjective assessment relies heavily on clinician knowledge of physical and 
cognitive impairments associated with ACh drugs. The objective approach makes use of 
physical or cognitive rating scales to quantify drug-related ACh effects, for example AIMS 
(the Abnormal Involuntary Movement Scale). Other types of published lists that have 
been developed are those based on clinican experience and objective measures. An 
example of this would be the Beer's criteria, which is a list of drugs which should be 
avoided in the elderly (Beers 1997; Fick et a1 2003). 
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The advantage to using this method is that it can serve as an aid or a guide to help a 
clinician decide the degree of risk an ACh drug may pose for an individual. The 
limitations are that it depends on the clinician's perspective, knowledge, and experience. 
The list must be combined with clinical judgement and then applied to each practice 
setting. There is no standardized, comprehensive ACh drug list available. Even with the 
combination of clinical tools such as the MMSE, which is not sensitive enough to detect 
mild drug-induced cognitive changes produced by ACh drugs, other tools such as the 
AIMS test have not been validated to ensure accuracy in detecting physical changes due to 
ACh drug reduction or discontinuation. 
Table 6. Drugs with Definite or Possible ACh effects 
DEFINITE EFFECTS: 
Antispasmodics GI: atropine, belladonna alkaloids, clinidium-chlordiazepoxide, dicyclomine, diphenoxylate, 
I hyoscyamine, scopolamine I 
urinary: oxybutynin, tolterodine I 
muscle: carisoprodol, chlorzoxazone, cyclobenzaprine, metaxalone, methocarbamol, orphenadrine 
1 Antidepressants TCA (amitriptyline, clomipramine, desipramine, doxepin, imipramine, nortriptyline) 
Antipsychotics olanzapine, perphenazine, promazine, thioridazine 
I Antiparkinsons benztropine, trihexyphenidyl 1 
Antihistamines chlorpheniramine, cyproheptadine, dcxchlorphcniramine, diphenhydraminc, hydroxyzine, meclizine 
Antiemctics dimenhydrinate, prochlorpcrazine, promethazine, uimethobenzamide 
Benzodiazepines alprazolam, clorazepate, ehlordiazepoxide, diazepam, flurazepam, oxazepam 
Cardiovascular disopyramide, procainarnide 
POSSIBLE EFFECTS: 
Antipsychotics chlorpromazine, clozapine, fluphenazine, haloperidol, olanzapine, quietapine, risperidone, 
thiothixene, trazodone, 
Antidepressants SSRIs (escitalopram, citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline) 
Antidiarrheal diphenoxylate 
I Cardiovascular captopril, digoxin, dipyridamole, doxazosin I 
Miscellaneous codeine, prednisolone, prednisone 
Adapted from references: Flacker et al., 1998; Mintzer 2000; Tune 2001; Miller 2002; Roe et al., 2002; Fick et al., 2003; Mulsant et al., 2003; Mann et al., 2003; 
Defilippi 2003; Scheife et al., 2005 
C. Measurement of individual drug-related ACh activity 
This method also uses the radioreceptor assay but in vitro (use of a standard 
concentration of a drug instead of patient's serum) to identify the ACh activity of 
individual drugs (Tune et al., 1991, 1992, 1993, 1999,2000). Many of these studies have 
looked at drugs that are commonly used in the elderly. 
The advantage to using this method is that it allows for the direct comparison of 
ACh activity of different drugs using atropine equivalents. The higher the atropine 
equivalent the more likely the drug will express ACh properties. One drawback is it does 
not account for varying drug dosages, pharmacokinetics, or differences due to individual 
patient physiology. Another limitation is that standardized drug concentrations may not 
reflect the concentration achieved at physiological conditions, nor of metabolites or the 
effects of protein binding. 
D. Measurement of individual muscarinic receptor affinity in vitro 
This method focuses on the drug-receptor interaction through direct measurements 
of receptor affinity by comparing the competitive binding between a radiolabeled 
muscarinic-cholinergic agonist and a study drug with muscarinic ACh receptor. 
It could be used clinically to compare the relative differences in muscarinic 
receptor affinity as an indicator of a drug's ACh activity. The limitations of this method 
are that a drug's ACh activity is relative to the drug concentration necessary to produce 
50% binding inhibition of a radiolabeled cholinergic agonist. There is also very limited 
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published data of dissociation constants for many drugs, which limits the utility of this 
approach. 
E. Combination 
There has been some research done using a combination of the above methods to 
measure ACh burden, each combination different from the other. One attempt to bring 
clinical utility to SAA is through using it to validate an ACh scale that can be used in 
practice to assess ACh burden (Carnahan et al., 2002). Carnahan et al., modified the 
original ratings of the Clinician-rated ACh scale (Han et al., 2001) only if there was 
compelling evidence such as receptor binding studies or clinically documented ACh effects 
to warrant the change. They then used SAA to validate the modified version (mCr-ACh 
scale) to assess ACh burden. The mCr-ACh scale rates the ACh nature of each medication 
on a scale of 0-3; 0 has no known ACh properties, 1= potentially ACh as evidenced by 
receptor binding studies, 2 = ACh effects sometimes noted but usually from excessive 
doses, and 3 = markedly ACh. Scores of the individual drugs taken by study participants 
were summed to determine their ACh burden. They found significant correlation between 
SAA and the mCr-ACh scale but the scores only explained a small variance in the 
observed SAA among the study participants which could be due to some of the limitations 
of this method. A limitation to the mCr-ACh scale is that it does not allow for differences 
in dosages nor take into account the differences in subject pharmacokinetics. By lumping 
ACh drugs into general categories it assumes that they are equally ACh when in fact this is 
most likely not the case. Another limitation is in the calculation of the burden score, by 
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summing the scores it assumes that two drugs each with a rating of two would be equally 
ACh to one drug with a rating of 4. 
Another approach that has been used is to multiply the atropine equivalent for a 
particular drug, as determined by antimuscarinic radioreceptor assay, by the total daily 
dosage and then sum the products to generate an ACh score (Tune et al., 198 1, 1992; 
Francis et al., 1990). 
Another method is to take the class of the drug and multiply it by daily effective 
dosage level number to give a drug risk number (Summers 1978). This method also 
attempts to classify drugs by their ACh properties or effects and assigns them a number (1 - 
3). The class of drug was classified as class I- known synergistic effect with ACh agents, 
but not known as a direct cause of acute organic mental syndrome; 11- known to cause 
delirium, but currently not documented to have CNS ACh properties; 111- known to cause 
delirium reversed by CNS active anticholinesterases or known to have CNS ACh effect 
and to cause delirium. It then defines daily effective dosage based on a therapeutic dosage 
range given over a 24 hour period and assigns the dose a number. The criteria for daily 
effective dosage was defined as dosage level I- that dose range which would not give 
therapeutic effect for a 24 hour period; 11- dose range which gives a therapeutic effect for a 
24 hour period; 111- dose range which exceeds the usual therapeutic range for a 24 hour 
period. It is these two assigned numbers that are multiplied together to calculate the drug 
risk number. 
Schor et al., 1992, used a different approach for assessing ACh burden. In this 
study they used hospital admission records and counted each dose given, so that the tallied 
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number, indicating the total number of ACh drugs received by the patient, was equal to the 
total number of doses given. The limitation of this method did not take into account ACh 
exposure, dose exposure nor ACh binding affinity. 
Marcantonio et al., 1994, studied dose response effect of benzodiazepines and ACh 
drugs and delirium in postoperative patients. They classified ACh exposure as either low 
or high depending on dose administered and whether or not it was given in single or 
multiple doses. The limitations with this method are it only looks at dose exposure, it does 
not take into account ACh potency or binding affinity. 
Cao et al., 2006, in their calculation of ACh burden, normalized ACh exposure by 
taking the ACh dose given and dividing it by the sum of the ACh dose given with the 
minimum recommended daily dose. 
In summary, there is not one standardized or universal method of measuring ACh 
burden. There have been multiple approaches and each has positive and negative 
characteristics. Finding a method that contains all of the positive characteristics of these 
methods and eliminates potential areas of subjectivity and has clinical utility would be 
ideal, but much research is still needed to create an ideal method of assessing ACh burden 
for clinicians caring for the geriatric population. 
CHAPTER 3 Methodology 
I. Subjecflatient Definition 
A. Population 
Hospitalized patients > 65 years of age that have documented dementia as defined 
by ICD-9 codes (Appendex A) or inferred dementia based on use of drug therapy used in 
the treatment of dementia (Appendix A) during hospitalization were studied. This 
evaluation was conducted using the university Health System Consortium (UHC) 
Clinical Database. The UHC is an alliance of 90 academic health centers in the US. The 
UHC Clinical Database (CDB)-Pharmacy database contains a comprehensive collection 
of procedure and diagnoses-specific data derived from discharge abstract summaries and 
UB-92 data, coupled with specific medication use from charge transaction masters and 
patient billing files for all inpatients at participating (currently 42) centers. UHC maps 
members' charge transaction masters (CTM) drug descriptions into a common pharmacy 
lexicon, standardizing descriptions to achieve reporting at the fundamental drug level. 
Four quarters (12 months) of data was evaluated from October 2003 to September 2004. 
Data was available for this analysis through a data use agreement between Virginia 
Comnlonwealth University (VCU) and UHC. The data collection, analysis and reporting 
was consistent with this agreement and compliant with HIPAA privacy provisions. No 
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individual patient identifiers were maintained in the study data set to preserve patient and 
health system confidentiality. This study was reviewed by the VCU Office of Research 
Subject Protection Institutional Review Board and found to qualify for exemption from 
federal regulations requiring IRB review and approval. No safety reporting was 
performed because the study is a retrospective analysis of a dataset that does not contain 
individual patient and health system identifiers. 
B. Sample Size 
There are 12,48 1 hospitalized elderly patients > 65 years of age with dementia. Of 
the 12,48 1 hospitalized elderly patients, 6926 were on ChEi therapy. 
11. Study Design and Data Collection 
A. Design 
This study is a prevalence survey of ACh medication (Appendix B) use in a 
hospitalized setting in individuals 2 65 years of age with dementia on or not on ChEi 
therapy. Those on a ChEi and an ACh were compared to those on a ChEi and no ACh. 
Another comparison made was between those on an ACh and a ChEi to those on an ACh 
and no ChEi. 
B. Data Collection 
Patients 2 65 years of age in the database were subdivided into two mutually 
exclusive groups: 1) patients on ChEi therapy or NMDA therapy (Appendix A) use 
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during hospitalization and not receiving ACh (Appendix B), and 2) patients on ChEi or 
NMDA therapy (Appendix A) use during hospitalization and receiving ACh (Appendix B). 
The total number of patients in each group was determined. ACh medication use was 
determined for each patient in each group. The following ACh medications with central 
nervous system activity were included in this review (Piecoro et.al., 1998; Semla et.al., 
2001): tricyclic antidepressants (amitriptyline, doxepin, imipramine, nortiptyline, 
desipramine), sedating antihistamines (diphenhydramine, promethazine, hydroxyzine), 
antiparkinson's drugs (benztropine, trihexyphenidyl), urinary antispasmodics (oxybutynin, 
tolterodine), gastrointestinal antispasmodics (atropine, scopolamine, hyoscyamine, 
belladonna alkaloids, dicyclomine), or antipsychotics (AP) (chlorpromazine, clozapine, 
promazine, thioridazine, olanzapine). The average dose per days of therapy and days of 
therapy for each centrally-acting ACh prescribed, length of stay (outcome measure), and 
potential confounders: age, sex, race, presence of delirium, from where they were admitted 
from (community, institutional setting, or transfer) and whether discharged to comniunity 
or institutional setting was determined for each patient, and disease severity. The UHC 
database accounts for severity of illness and comorbid conditions variables (severity score) 
using a combination of the RDRGs and the UHC Complication Profiler (UCP) which is 
based on original research by Lisa Iezzoni at Beth Israel Hospital (Iezzone et al, 1992; 
Kalish et al.,, 1995; Iezzone et al.,, 1994). Four levels of severity are defined: Baseline (no 
substantial CCS), moderate CCS, major CCS, and catastrophic CCS (surgery). 
All patients using ChEi during hospitalization were identified. The name of the 
ChEi, the average dose per day and the days of cholinesterase inhibitor therapy were 
determined for each patient. A flow chart describing the specific data elements collected 
can be found in Appendix C. 
The entire population of dementia patients was used for specific aims 1,2, and 3. It 
could not be determined by looking at the data whether 1) multiple strengths of the same 
drug for the same patient were given as one dose or as multiple doses or, 2) if those 
patients who may have received multiple doses of a drug with different days of therapy 
were being titrated up or off a medication or if there was some overlap between doses, 
these individuals were excluded from the remaining analyses to avoid assumptions that 
could possibly over or underestimate the calculated ACh burden score. In other words, 
patients who received more than one dose strength of an ACh medication during their 
hospital stay and the days of .therapy were different from each other and from observed 
LOS were excluded from the analyses for specific aims 4 ,5 ,6 ,7  and 8. 
Patients included for the remaining analyses (specific aims 4, 5, 6, 7, and 8) were: 
1) those who received one strength only for one ACh drug, or 2) those who received more 
than one ACh drug during their hospital stay and had multiple rows of data which had to 
be combined into one row per patient, or 3) those patients who received different strengths 
of an ACh drug but their days of therapy were the same as their observed LOS then the 
doses were combined and counted as one ACh drug and the combined dose was used in 
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calculating their ACh burden score. ACh burden was determined for each patient as dose 
[low, medium, high] x days of therapy x ACh potency [low, medium, high] summed across 
all ACh drugs. High doses were assigned a 3, medium assigned a 2, and low assigned a 1. 
Doses were defined using dosing recommendations for the elderly compiled in the 
Geriatric Dosage Handbook (Semla et al., 2005). Days of therapy was definded as: acute = 
< 2 days of therapy and thus assigned a 1 or chronic being >2 days of therapy and thus 
-
assigned a 2 into the calculation. High ACh potency was assigned a 3, mediuni assigned a 
2, and low ACh potency assigned a 1 for use in the above formula. ACh potency was 
estimated based on comparative drug tables compiled in the Geriatric Dosage Handbook 
(Semla et al., 2005) (AP, antidepressants, and antihistamines) and clinical pharmacology 
data in the published literature. The dose and potency definitions are in Appendix E. 
Some of the variables in the data set had too many levels and therefore had to be 
condensed to fewer levels for the analyses, such as admission source had 18 levels, 
discharge status had 2 1 levels, and primary diagnosis had 13 52 levels and were recoded as 
3,4, and 26 levels respectively. The definitions of how the variables were recoded for 
theses analyses can be found in Appendix D. There were no outliers excluded from the 
data analyses. 
111. Data Analysis 
All statistical analyses were perfomled using JMP 5.1. Assumptions of each test 
were checked before tests were performed. If the assumptions were not met then 
appropriate data transformations were performed. The significance level was set at 0.05. 
A. Specific Aim #1 
The first aim was to determine the prevalence of ACh medication use in 
hospitalized elderly patients 2 65 years of age with dementia. Prevalence of ACh drug use 
in patients with dementia was calculated by dividing the number of patients taking at least 
one ACh drug by the total number of patients with dementia (diagnosed and inferred). 
Characteristics of the groups were compared using tests of statistical significance 
appropriate for each variable type (Chi-square or t-test). The observed LOS was not 
normally distributed and therefore its log transformation was used for analyses and back 
transformed for reporting purposes. 
Prevalence of AChdementi, = 3 
Total # of dementia patients 
B. Specific Aim #2 
The second aim was to determine ACh prevalence in hospitalized elderly patients 
with dementia (Alzheimer's disease or other dementias) on ChEi. Prevalence of ACh drug 
use in patients with dementia and on ChEi therapy was calculated by dividing the number 
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of patients taking at least one ACh drug and a ChEi by the total number of patients taking a 
ChEi. 
Prevalence of ACh, ChEi dementia patients = # of patients on ChEi and > 1 ACh drug 
Total # of dementia patients on ChEi 
C. Specific Aim #3 
The next aim was to compare the ACh prevalence between hospitalized elderly 
patients with dementia using and not using ChEi therapy. Prevalences of hospitalized 
elderly patients taking ACh (dependent categorical (Y/N) variable) with or without a ChEi 
(independent categorical (Y/N) variable) were compared using 2. 
D. Specific Aim #4 
The fourth aim was to compare ACh burden between hospitalized elderly patients 
with dementia on and not on ChEi therapy. 
The independent variable is ChEi therapy and is dichotomous, the dependent 
variable is ACh burden and was assessed as a continuous variable. Test for equal 
variances was done first to test for significant differences between group sizes. Since there 
was a significant difference, the t-test for unequal variances was used to assess the 
difference between the two groups. 
If ACh burden is significantly different between groups then it would be expected 
that the total number of ACh drugs would also be different between groups. The total 
number of ACh drugs (dependent continuous variable) with a ChEi was compared to those 
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without a ChEi. Test for equal variances was done first to test for significant differences 
between group sizes. Since there was a significant difference the t-test for unequal 
variances was used to assess the difference between the two groups. 
E. Specific Aim #5 
The fifth aim was to characterize prescribing patterns of ACh medications in the 
hospitalized elderly, particularly those with dementia with or with out ChEi therapy. 
The percentage use for each ACh drug in each group of patients, those with or 
without ChEi therapy, was calculated by dividing the number of courses of therapy for that 
drug in that group of patients by the total number of courses of therapy for all ACh drugs. 
A patient can have more than one course of therapy if they received more than one ACh 
drug during the hospitalization. Average daily dose and average days of therapy for each 
ACh drug was calculated to determine whether some medications are being used at higher 
or lower doses relative to their labeled dosage range. 
F. Specific Aim #6 
The following aim was to compare the prescribing patterns of urinary 
antispasmodics, GI antispasmodics, sedating antihistamines and antispychotics (AP) 
between hospitalized elderly patients with dementia using and not using ChEi therapy. 
There are two different groups being analyzed, those using or using on ChEi 
therapy which is the independent dichotomous variable. Each group has the dependent 
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variables of urinary antispasmodics, GI antispasmodics, and AP and each was analyzed 
between groups using 2. 
G. Specific Aim #7 
The following aim evaluated and compared the impact of ACh medication use in 
hospitalized dementia patients on LOS, discharge status, and having delirium while in the 
hospital. A stepwise regression analysis was conducted to evaluate whether ACh use 
(categorical: yeslno) was associated with increased LOS in elderly patients with dementia. 
The dependent variable was log LOS and the independent variables evaluated were age, 
sex, race (White, Black, other (Asian, Hispanic, Native ArnericanlEskimo, unknown), 
severity score (baseline/moderate/major/catastrophic), admission source 
(community/instit~~tion/other), discharge status (community/institution/other/died), and 
whether or not the patient was coded for delirium, received an ACh drug or received a 
ChEi. Criteria for the stepwise regression were defined as the probability of F or enter 5 
0.05 and probability of F to remove > 0.10. 
Logistic regression analysis was used to evaluate the association between ACh 
medication use and discharge status (change from community to institution) and also 
whether or not the patient was documented as having delirium during their hospital stay. 
H. Specific Aim #8 
The last aim of the study was to evaluate and compare the impact of ACh burden in 
hospitalized dementia patients on LOS, discharge status, and having delirium while in the 
hospital. 
For each group (ChEi with ACh and no ChEi with ACh), severity score, 
documented delirium, ACh burden, admission source, discharge to community/institution/ 
/other setting, age, race, and sex was incorporated as covariates in the regression model. 
ACh burden was assessed as a continuous independent variable for patients who received 
at least one ACh drug. It is expected that increasing exposure will be associated with 
increased LOS, change in discharge status between where they were admitted from and 
where they were discharged to, and having delirium while in the hospital. 
The independent variable ACh burden and the dependent variable LOS was 
assessed as continuous variables and therefore was analyzed using a linear regression after 
log transformation of LOS. 
Change in status between where they were admitted fiom and where they were 
discharged to was assessed as a dichotomous variable (institution, non-institution) and 
therefore analyzed using logistic regression. 
Whether or not the patient was documented as having delirium while in the hospital 
was also assessed as a dichotomous variable and analyzed using logistic regression. 
CHAPTER 4 Results 
I. Specific aim #1 
The first part of aim #1 was to compare characteristics between the groups and test 
for significance. Table 7 shows the characteristics of the study population at admission. 
There were 12,48 1 dementia patients with a mean age of 81.2 years, SD = 7.2 years with 
60.3% of the population being female. This is representative of the elderly (265 years) 
population with dementia. Eighty-four percent of the dementia population was admitted 
from the community, of which 46.9% were admitted with a moderate severity score. The 
most common primary diagnosis was circulatory/vascular/heart disease in the dementia 
population. 
The population characteristics were normally distributed. There were missing 
values listed as unknown (n=68) for severity scores in the data set. There were no 
significant differences in age (p = 0.9), sex (p = 0.8), race (p = 0.4), severity score (p = 0.3) 
nor admission source (p = 0.6) between the four groups (no ChEi with no ACh, no ChEi 
with ACh, ChEi and no ACh, or ChEi and ACh). The observed LOS was not normally 
distributed and therefore its log transformation was used in analyses. 
Table 7. Population characteristics 
+=yes; - = n o  
*Average LOS was calculated from the LOG transformation of LOS observed and then back transformed 
dz = disease; d/o = disorder; ccs= complications & comorbidities 
Age (years) 
Mean (5  SD) 
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The second part of aim # 1 was to determine the prevalence of ACh medication use 
in hospitalized elderly patients 2 65 years of age with dementia. There was a total of 4086 
dementia patients who received at least one ACh drug during their hospitalization. The 
ACh prevalence aniong all dementia patients was 4086112,481 = 32.7%. There was not a 
significant difference in ACh prevalence between those admitted from an institution and 
those admitted from the community. 
11. Specific Aim #2 
The second aim of the study was to determine ACh prevalence in hospitalized 
elderly patients with dementia on ChEi therapy. There were 2485 patients on ChEi therapy 
that also received at least one ACh drug. ACh prevalence in the dementia patients using 
ChEi therapy was 248516926 = 35.9% and 160115555 = 28.8% for those not using ChEi 
therapy. 
There were a total of 7275 courses of ChEi therapy given. Table 8 shows the ChEi 
utilization for those also receiving ACh drugs and those not receiving ACh drugs. 
Table 8. ChEi utilization by group 
-ACh 
Average Average Average Average 
Drug Frequency (%) dose (mg) therapy (days) Frequency (%) dose (mg) therapy (days) 
Donepezil 53.4 10.2 5.1 30.8 9.9 6.3 
Galantamine 4.9 16.7 5.1 2.6 19.3 6.3 
Rivastigmine 5.2 8.4 5.9 3.1 7.2 6.7 
Tacrine 0.04 29.4 3 0.0 0.0 0.0 
111. Specific Aim #3 
The third aim was to test for significant differences in ACh prevalence between 
dementia patients on ChEi therapy and dementia patients not on ChEi therapy. Table 9 
shows the total number of individuals in each group and the respective proportions 
receiving an ACh medication. There were 4086 dementia patients who received at least 
one ACh medication during their hospital stay. The ACh prevalence was significantly 
higher in the dementia patients who receive ChEi therapy than those who did not receive 
ChEi therapy (chi-square 70.1, d e q ,  p < 0.0001). 
Table 9. Proportion receiving ACh within each group 
IV. Specific Aim #4 
count received ACh 
(proportion) No Yes total 
The next aim of the study was to compare ACh burden between hospitalized 
received 
ChEi 
elderly patients with dementia using and not using ChEi therapy. After excluding those 
No 3954 (.471) 1601 (.392) 5555 (.445) 
yes  4441 (.529) 2485 (.608) 6926 ( 3 5 )  
patients who received multiple different doses of an ACh that had different days of therapy 
total 8395 (1 .O) 4086 (1 .O) 12481 (1.0) 
from each other and from the observed length of stay, there were 3486 patients remaining 
of the original 4086 patients for this analysis. Table 10 shows the mean total number of 
ACh drugs and ACh burden for dementia patients taking and not taking ChEi therapy. 
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ACh burden was compared between ACh with ChEi and ACh with no ChEi, using 
Welch ANOVA due to a significant difference between the group sizes (F(1,3 180.6) = 
9.9, p = 0.0017). When using the t-test for unequal variance, ACh burden was 
significantly higher (difference = 0.5,95%CI [0.2,0.8], p = 0.0017) in those patients 
receiving a ChEi than those who were not receiving a ChEi. 
The total number of ACh medications was compared using Welch ANOVA and 
were found to be significantly different (F(1,3 176.7) = 8.9, p = 0.0029). When using the t- 
test for unequal variance, the total number of ACh drugs was higher in patients receiving 
ChEi than those who were not (difference = 0.05,95% CI [0.02, 0.081, p = 0.0029). 
Table 10. ACh medication use 
mean std dev 95% CI 
dementia pts +ChEi 
# ACh drugs 1.2 0.5 1.18 1.23 
ACh burden 7.1 4.9 6.9 7.3 
dementia pts -ChEi 
# ACh drugs 1.2 0.4 1.1 1.2 
ACh burden 6.6 4.3 6.4 6.9 
V. Specific Aim #5 
The purpose of this aim was to characterize prescribing patterns of ACh 
medications used in the hospitalized elderly, particularly those with dementia with or with 
out ChEi therapy. There were 55 10 ACh courses given to 3486 hospitalized elderly 
patients with dementia. Table 11 shows the frequency of use for a particular ACh drug and 
its average dose and days of therapy for dementia patients that did or did not receive ChEi 
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therapy. The most frequently used ACh drugs were: tolterodine 4.4%, oxybutynin 6.4%, 
atropine 7%, promethazine 12.2%, olanzapine 16.8%, and diphenhydramine 19.7%. 
Olanzapine, tolterodine, and oxybutynin were given chronically (average days of therapy 
were approximately 5 for each) and accounted for 27.6% of all prescribed ACh, whereas 
atropine, promethazine and diphenhydramine were mainly given acutely (average days of 
therapy were approxinlate 1.5 for each) and accounted for 38.9% of all prescribed ACh. 
The average dose for most of the ACh drugs given were less than the suggested 
recommended maximum dosage per the Geriatric handbook. The average 
diphenhydramine dose was nearly double and average clozapine was nearly triple the 
recommended maximum dosage listed in the Geriatric handbook. The average promazine 
and nortriptyline doses given were also higher than the recommended maximum dosage 
listed in the Geriatric handbook. The average doses of oxybutynin and tolterodine given 
were slightly higher than the recommended maximum dosage listed in the Geriatric 
handbook. 













frequency dose 95% CI tx 1 frequency dose 95% CI tx 
- - 
(%) (mdf (dose) (days) 
0.6 37.5 27.7, 47.3 5.3 
(Table 11 continued from page 49) 
I -ChEi 
Chlorpromazine 0.3 48.2 21.2, 75.2 77.7 43.2, 112.2 
Clozapine 1 0.1 83.1 39.6, 126.6 4.7 270.6 181.3, 360.0* 4.5 
ACh Drug 
Benztropine 
Desipramine 1 0.1 83.3 22.0, 144.7 3.2 1 0.0 0.0 0 . 0 ~  0.0 1 
Dicyclomine 0.1 28.6 19.2, 37.9 21.7 10.0, 36.0* 
Diphenhydramine 1 11.6 44.8 42.7, 46.9 1.5 45.4 42.8, 48.0 1.5 
Ave 
frequency dose 95% CI Ave tx 
w )  ( m d t  (dose) (days) 









frequency dose 95% CI Ave tx 
("h) ( m d t  (dose) (days) 
0.8 1.5 1.2, 1.8 3.9 
I ~romazine 1 0.02 75.0 75.0~ 1.0 1 0.04 25.0 25 .0~ 1.0 I 
I Promethazine 1 7.6 33.3 31.5,35.1 1.6 1 4.6 29.7 28.2, 31.2 1.7 / 
Scopolamine I Thioridazine 
Ave= average; tx= therapy 
Tolterodine tartrate 
Trihexyphendyl 
VI. Specific Aim #6 
The purpose of this aim is to compare the prescribing patterns for the ACh classes: 
urinary antispasmodics, GI antispasmodics, sedating antihistamines and ACh 
antispychotics between hospitalized elderly patients with dementia on and not on ChEi 
dosage is in mg except where otherwise noted 
* when the lower 95% CI was 0 due to their being only a few doses with wide spread, the 95% CI was entered as the minium and maximum dosages 
' there was either no doses, one dose, or two doses given at the same dose 
3.1 5.8 4.4, 7.2 4.6 
0.1 6.9 2.0, 29.0* 4.8 
1.3 5.0 3.3, 6.7 4.5 
0.1 4.2 0.9, 7.6 2.9 
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therapy. Table 12 shows the number of patients in each group, those receiving and not 
receiving ChEi therapy, that received at least one ACh dose from each ACh class. There 
were no significant differences in the proportion of AP (p =0.6), GI antispasmodics 
(p = 0.7), nor sedating antihistamines (p = 0.4) doses given between hospitalized dementia 
patients receiving and not receiving ChEi therapy. There was a significant difference in 
the proportion of urinary antispasmodics (p <0.0001) given between hospitalized dementia 
patients receiving and not receiving ChEi therapy. 
Table 12. Proportion receiving ACh class per group 
ACh drug class -ChEi +ChEi total 
Antipsychotic 455 (0.40) 678 (0.60) 1133 
GI antispasmodic 178 (0.39) 282 (0.61) 460 
Sedating antihistamine 1098 (0.52) 101 1 (0.48) 2109 
Urinary antispasmodic 177 (0.30) 407 (0.70) 584 
VII. Specific Aim #7 
Aim #7 evaluated and compared the impact of ACh medication use in hospitalized 
dementia patients on LOS, discharge status, and having delirium while in the hospital. 
There were 1 1,88 1 of the original 12,48 1 patients for this analysis after excluding 600 who 
had received multiple different ACh doses with different days of therapy from each other 
and from the observed LOS. An additional 60 patients were omitted from the analyses 
because of missing severity score values. Table 13 is a correlation matrix that shows the 
relationships among the study variables. 
Table 13. Correlations among independent and dependent variables 
A. ACh impact on LOS 
The results from specific aim #3 showed that there was a significant difference 
between ACh use for those who receive or do not receive ChEi therapy. ANOVA was 
performed to test the significance of an interaction between ChEi therapy and ACh 
medication use with LOS. Since there was evidence of a non-ignorable interaction 
(p=.0008), of whether or not one received an ACh or a ChEi therapy on LOS, the effect of 
one factor will be considered separately for each level of the other factor. The effect of 
ChEi therapy will first be considered within the two ACh groups. Within the subgroup of 









Log LOS obsvd 
Sex 
Patient coded for 
delirium? 
whether they received ChEi therapy (unadjusted p<.0001, Bonferonni cut-off = .0125), 
Log Patient 
Age Received Received Severity Admission Discharge LOS coded for 
(yrs) Race ACh ChEi Score Source Status obsvd Sex delirium 
1 .oo 
-0.055 
p < o o o ~  1.00 
-0.065 -0.068 
p< 0001 p< 0001 1.00 
-0.082 -0.14 0.069 
p< 0001 p< 0001 p<.0001 1 .00 
0.020 0.069 -0.051 
p= 03 -0.010 p<.ooo~ p< 0001 1.00 
-0.017 
-0.0009 -0.007 0.0036 p=os -0.0043 1.00 
0.11 -0.031 0.026 -0.11 0.23 
p< 0001 p= 002 p= 004 p< 0001 p< 0001 0.0044 1 .00 
-0.047 0.12 0.060 0.28 0.01 1 0.17 
p<.ooo~ 0.010 p<.mol p< 0001 p< 0001 p<.oool P<.OOOI 1.00 
0.14 0.043 0.0022 -0.07 -0.036 0.0057 0.0005 -0.031 
p< 0001 p<.ooo~ p<.ooo~ p<.ooo~ p<.ooo~ p<.ooo~ p<.ooo~ P<.OOOI 1.00 
-0-091 0.024 0.054 -0.023 
0.014 -0.017 0.0067 p < o o o ~  0.013 0.0017 p=.01 p < o o o ~  p=.01 1.00 
5 2 
those that received ChEi therapy had a LOS of 1.2 days longer (SE= 1.0). Within the 
subgroup of patients who received an ACh there was no significant difference in LOS 
depending upon whether or not they received ChEi therapy (unadjusted p=.03, Bonferonni 
cut-off = .0125). Within the subgroup of patients who did not receive a ChEi there was a 
significant difference in LOS depending upon whether or not they also received an ACh 
drug (unadjusted p<.000 1, Bonferonni cut-off =.O 125), those that also received an ACh 
had a LOS of 1.3 days longer (SE=1.0). Within the subgroup of patients who did receive a 
ChEi there was a significant difference in LOS depending upon whether or not they also 
received an ACh drug (unadjusted p<.000 1, Bonferonni cut-off = .0 125), those that 
received an ACh had a stay of 1.1 days longer (SE=1.0). 
The above results were confirmed by repeating the analysis with the independent 
variable as group (no ACh with no ChEi; no ACh with ChEi; ACh with no ChEi; and ACli 
with ChEi) and the groups were compared with Tukeys HSD multiple comparison. 
Further analysis on the variables and the three most prevalent diagnosis on admission were 
compared between subgroups to further explain these results. 
Those with no ACh therapy (n=8395) with their ChEi therapy, had a significantly 
longer LOS than those who did not receive ChEi therapy. Those on ChEi therapy were 
significantly younger and white (p<.0001), were less likely to be coded for delirium 
(p<.0001), were significantly more likely to have a severity score of 4 (catastrophic), 2 
(moderate), or 1 (baseline) (p<.0001), and more likely to be discharged to either the 
community or other (other, unknown, transfer). Also the proportion of men compared to 
the proportion of women was significantly higher for those not on an ACh (p<.0001). 
Those on a ChEi were significantly more likely to be admitted for 
circulatory/vascular/heart disease (p<.0001). 
In those patients who were not on ChEi therapy (n=533 1) but received at least one 
ACh had a significantly longer LOS than those who did not receive an ACh. They were 
also significantly younger (p=.0003), more likely to be white (p<.0001), significantly more 
likely to have a severity score of 3 (major) or 4 (catastrophic) (p<.0001), and more likely 
to be admitted for circulatory/vascular heart disease (p=.02). There was a significant 
difference in discharge status (p=.02) depending on whether or not they were also taking 
an ACh. Those on ACh were more likely to have a discharge status of 3 (other, unknown, 
transfer) or 4 (expired) (p=.02), those not on ACh were more likely to be discharged to the 
community, but there were no significant differences in discharge status to an institution 
whether or not they received an ACh. 
In those patients who were on ChEi therapy (n=6550) but received at least one ACh 
had a significantly longer LOS than those who did not receive an ACh. They were also 
significantly younger (p<.0001), more likely to be white (p<.01), a significantly larger 
proportion were female (p<.03), and significantly more likely to have a severity code of 3 
(major) or 4 (catastrophic). They was a significant difference in discharge status (p=.006) 
depending on whether or not they were also taking an ACh. Those on ACh were more 
likely to have a discharge status of 3 (other, unknown, transfer) or 4 (expired), those not on 
ACh were more likely to be discharged to the community, but there were no significant 
differences in discharge status to an institution whether or not they received an ACh. 
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A dose-response relationship with ACh administration (diphenhydramine) has previously 
established a significantly longer hospital stay (Agostini et al., 2005). 
To further confirm the above differences between groups, stepwise multiple linear 
regression was used to evaluate the impact of ACh medication use on LOS. ChEi therapy 
and the ACh-ChEi interaction were put into the stepwise regression model because of its 
significant interaction between the two. Independent variables entered the stepwise 
regression model in the following order: severity score, discharge status, whether or not 
they received an ACh, whether or not they received a ChEi, age, whether or not they coded 
for delirium, race, and then the ACh-ChEi interaction. The first three variables account 
for the majority of the change in the r2. Whether or not they received a ChEi and the ACh- 
ChEi interaction added 0.54% and 0.08% respectively, of the variability accounted for in 
the model. The model accounts for approximately 14% of the variability in LOS (r2 = 
0.1433) for elderly patients with dementia. The table 14 shows the median and average 
LOS for each of the groups. The model summary output from JMP is in Table 15. 
Table 14. LOS comparison between groups 
median mean 
Group (days) (days) 95% CI 
-ACh -ChEi 4.0 5.9 5.7 6.1 
Table 15. Model summary of ACh use (YIN) with Response: LOS 
Stepwise Fit 
Response: 
Log LOS obsvd 
Stepwise Regression Control 
Prob to Enter 0.050 
Prob to Leave 0.100 
60 rows not used due to missing values (severity score). 
Current Estimates 
SSE DFE MSE RSquare RSquare Adj Cp AIC 























Received ACh?{NO-YES)*Recieved ChEi?{NO-YES) 
Patient coded 4delirium?{NO-YES) 
Severity Score 2{ 1&2-3&4) 
Severity Score 2{1-2) 
Severity Score 2{3-4) 
Admission Source 2{1&2-3) 
Admission Source 2{1-2) 
Discharge Status 2{ 1 -4&2&3) 
Discharge Status 214-2&3) 

















SS F Ratio Prob>F 
- 
Step Parameter Action "Sig Prob" Seq SS RSquare Cp p 

































B. ACh impact on delirium 
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evaluate the impact of ACh medication use and whether or not the patient was coded for 
delirium, first with ACh use alone and then including the ACh-ChEi interaction. 
Even after taking into account the other variables, ACh medication use was still not 
significant in whether a patient coded for delirium or not (p=.66). When analysis was 
repeated taking into account ChEi use and the ACh-ChEi interaction, ACh medication use 
became even more non significant in whether a patient coded for delirium or not (p=.74). 
The ACh-ChEi interaction was also non-significant (p=.5 1) but ChEi use was significant 
(p<.0001). ACh medication uses' lack of significance could be due to the inability from 
the database to differentiate whether or not the ACh drug was being used to treat delirium, 
such the case with the use of many AP or if it was causing the delirium. The lack of 
significance could also be due to whether or not a patient actually gets documented as 
having delirium during their hospital stay. Accurate documentation of delirium relies 
heavily upon patient records and not billing codes. In the 11,881 patients used in this 
analysis, only 5% of the patients were documented as having delirium, which is grossly 
understated compared to numerous studies which document 14-56% (Rosin 1966; 
Hodkinson 1973; Bergman 1974; Seymour 1980; Chisholm 1982). 
C. ACh impact on discharge status 
Chi-square indicated a significant difference (p=.05) between community-dwelling 
elders discharged to either community or an institution depending on whether or not they 
received an ACh drug. There is a greater likelihood of being discharged to an institution if 
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they received an ACh drug (p=.03). A logistic regression was used to evaluate the impact 
of ACh medication use on discharge status, first ACh use alone and then including the 
ACh-ChEi interaction. 
After taking into account the other variables, ACh medication use was no longer 
significant (p = .49). When the analysis was repeated to include ChEi and the ACh-ChEi 
interaction, ACh medication use became even more non- significant (p = .98). The ACh- 
ChEi interaction was also non-significant (p=.20), but ChEi use was significant @<.0001). 
VIII. Specific Aim #8 
The purpose of this last aim was to further evaluate the impact of ACh burden in 
hospitalized dementia patients on LOS, discharge status, and having delirium while in the 
hospital. ACh burden was slightly skewed to the left (median = 6, range [2,36]) and 
therefore its log was used in the following analyses. 
A. ACh burden and LOS 
A stepwise multiple linear regression will be used to evaluate the impact of ACh 
burden on LOS. Since it was previously shown that ACh use impacts LOS, this analysis 
attempted to look at a dose response relationship in only those patients who received at 
least one ACh drug. Independent variables entered the stepwise regression model in the 
following order: severity score, log ACh burden score, discharge status, whether or not 
they coded for delirium, age, race. The first three variables account for the majority of the 
change in the r2. The model accounts for approximately 17% of the variability in LOS (r2 
= 0.1701) for elderly patients with dementia. The model summary output from JMP is in 
Table 16. 
Table 16. Model Summary of ACh burden with Response: LOS 
Stepwise Fit 
Response : 
Log LOS obsvd 
Stepwise Regression Control 
Prob to Enter 0.050 
Prob to Leave 0.100 
8428 rows not used due to missing values (did not receive an ACh drug). 
Current Estimates 
SSE DFE MSE RSquare RSquare Adj Cp AIC 
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B. ACh burden and delirium 
A chi-square of ACh burden verses whether or not a patient coded for delirium 
showed no significant difference (p = .34). Even after taking into account the other 
variables, ACh burden still was not significant in whether a patient was coded for delirium 
ornot (p = .14). 
C. ACh burden and discharge status 
A logistic analysis of ACh burden (continuous variable) verses change in discharge 
status (community or institution) in community dwelling elderly showed no significant 
difference (p = .34). Even after taking into account the other variables, ACh burden still 
was not significant in discharge status of community dwelling elderly (p = .8). 
Chapter 5 Conclusions/Discussion 
I. Conclusion 
A. ACh prevalence 
A1 . Prevalence among hospitalized elderly dementia patients 
In this study, 32.7% of the hospitalized elderly patients received an ACh. This is 
consistent with past studies that have looked at prevalence of ACh use in nursing home 
patients. The Medicare utilization review found that 34.5% of patients were receiving 
ACh drugs (Seifert et al., 1983). Another study that looked at diphenhydramine use only, 
among hospitalized elderly patients found that 27% had received diplienhydramine during 
their hospital stay (Agostini et al., 2005). Blazer et al., reported that nearly 60% of 
nursing home residents and 23% of elderly people living in the community received drugs 
with ACh activity. 
A2. Prevalence among hospitalized elderly dementia patients on ChEi therapy 
ACh prevalence among the dementia patients on ChEi therapy was 28.8% which is 
consistent with the findings of past studies. Past studies that looked at state Medicaid 
administrative data claims found 13.5% and 35.4% of patients receiving a ChEi were also 
receiving an ACh drug (Slattum et al., 2001; Carnahan et al., 2004). Kogut et a1 looked at 
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the prevalence of community and LTC residents (2 45) that were enrolled in the Rhode 
Island Medicaid program who were dispensed a ChEi and a drug therapy that can impair 
cognition (list of 58 drugs). Nearly 60% of those receiving a ChEi also received drug 
therapy that can impair cognition (40 of the 58 drugs had ACh properties) (Kogul et al., 
2005). In a study by Carnahan et al., 35.4% of individuals of Iowa Medicaid beneficiaries 
(2 50) taking ChEi were also concurrently receiving an ACh drug (Carnahan et al., 2004). 
ACh drugs such as those used to treat urinary incontinence are frequently started after 
initiation of ChEi therapy. 
A3. Comparison between those on and not on ChEi therapy 
The prevalence of ACh drug use in this study was significantly higher in those 
patients who were receiving ChEi therapy compared to those who were not. Gill et al., 
found patients who were receiving ChEi therapy were 4.5% more likely to be prescribed an 
ACh medication than those not on a ChEi. Community-based elderly taking ChEi are 
more likely to receive an ACh and nearly one third of those taking a ChEi were also 
receiving an ACh (Gill et al., 2005). In this study there were no significant differences in 
ChEi therapy between those fi-om the community and those from an institution (p= .53). 
B. Comparison of ACh burden between those on and not on ChEi therapy 
The ACh burden was significantly higher in those patients on a ChEi compared to 
those individuals who were not on ChEi therapy. Since ACh burden was higher, it was a 
logical progression that the total number of ACh drugs would also be significantly higher. 
This would seem to make sense since current literature suggests that it is likely to be 
prescribed more than one ACh drug while on ChEi therapy. The total number of ACh 
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drugs received by an individual on ChEi therapy was significantly higher than those 
patients not on ChEi therapy (p =.0029). The study by Roe et al., that looked at 
community-dwelling elderly, pharmacy benefit management claims, of the 33% that were 
receiving an ACh, 26 % of them were also taking more than one ACh drug (Roe et al., 
2002). 
C. ACh prescribing patterns 
Olanzapine, tolterodine, and oxybutynin were given chronically (average days of 
therapy were approximately 5 for each) and accounted for 27.6% of all prescribed ACh, 
whereas atropine, promethazine and diphenhydramine were mainly given acutely (average 
days of therapy were approximate 1.5 for each) and accounted for 38.9% of all prescribed 
ACh. The most commonly used ACh drugs were the ones used for acute or prophylactic 
therapy, promethazine and diphenhydramine together accounted for 32%, 
diphenhydramine alone was almost 20% of all ACh prescribed. This is not surprising and 
is similar to the similar results as Beers et al., and Agostini et al., In an outpatient study of 
elderly patients of intermediate-care facilities in Massachusetts, more than 25% of them 
received some form of a sedative andlor hypnotic medication, with diphenhydramine 
accounting for 26% (1 4-4 1 % over all study sites) (Beers et al., 1988). In a study of 
hospitalized medical patients 70 years and older, 27% had received diphenhydramine 
during their hospitalization (Agostini et al., 2005). 
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There were no significant differences in the proportion of AP, GI antispasmodics 
nor sedating antihistamine use between those on and not on ChEi therapy, but there was a 
significant difference in the proportion of urinary antispasmodics that were prescribed 
between the two groups. Those receiving ChEi were significantly more likely to also 
receive a drug for urinary incontinence (oxybutynin or tolterodine). Use of cholinesterase 
inhibitors has been associated with an increased risk of receiving an ACh drug to manage 
urinary symptoms (Gill et a1 2005; Roe et al., 2002). 
D. ACh impact on LOS, delirium, and discharge status 
Dl .  LOS 
Since ACh and ChEi did not have independent effects, their separate effects on 
LOS could not be distinguished. When comparing the groups (no ACh with no ChEi, no 
ACh with ChEi, ACh with no ChEi, and ACh with ChEi) there was a significant difference 
in LOS across groups. There was not a significant difference in LOS in the subgroup of 
people taking an ACh with or without ChEi therapy. When put into order of group by its 
effects on LOS in equation form it looks like this: 
(ChEi with ACh) = (no ChEi with ACh) > (no ACh with ChEi) > (no ACh and no ChEi) 
When multiple regression was performed the variables that had the greatest 
significant effect on LOS were severity scores, discharge status, whether or not they were 
taking an ACh, age and delirium and accounted for 15% of the variablity. The low 
variability of the results observed could be due to a number of things. Many of the 
variables and response variables were significantly correlated with each other as per Table 
13. There is a significant interaction of ACh and ChEi drug use and also the fact that this 
model only took into account the variables for which data was collected on and not all 
variables that could possibly affect LOS. 
There was a significant difference in LOS between patients who did or did not 
experience delirium during their hospital stay (p<.0001), those that experienced delirium 
had a significantly longer LOS than those who did not. There was also a significant 
difference in LOS depending on where a patient was discharged to. 
D2. Delirium 
In this study it was found that only 5% of the population was documented as having 
delirium, which is grossly understated and could explain why no significant difference was 
found between ACh drug use nor ACh burden and whether or not a patient was coded for 
having delirium during their hospital stay. There have been numerous studies which have 
documented the occurrence of delirium in 14-56% of hospitalized elderly patients (Rosin 
1966; Hodkinson 1973; Bergman 1974; Seymour 1980; Chisholm 1982). One reason for 
the under documentation of delirium is that documentation of (Y/N) delirum relied on 
patient records and not a billing code. 
The inability to discern a direct relationship of ACh use or burden to delirium could 
be due to a number of things. The method used to measure ACh burden most likely was 
not sensitive enough. There was a case-control study (Marcantonio et al., 1994), a 
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prospective study (Francis et al., 1990) and a cohort analytic study (Schor et al., 1992) that 
were also unable to find a direct relationship between ACh use and delirium. These 
studies documented delirium based on the patient meeting CAM, DSM-111, with or without 
MMSE criteria and ACh use by either counting total number of doses received or noting 
whether or not the patient received an ACh drug. There have been 14 studies that have 
found a significant relationship between ACh drug use and the development of delirium all 
used either SAA, plasma ACh activity, or multiplying the atropine equivalents of the drug 
by the total daily dosage given and then summing them all for each ACh drug given to 
measure ACh burden. They also used at least one of several tests (Delirium symptom 
interview, battery of mental or psychological tests, DSM-111, CAM, or Cognitive 
performance scale) in documenting delirium. 
D3. Discharge status 
ACh use alone was significant in determining discharge status of community- 
dwelling elders to either community or an institution, but when other variables where taken 
into account, ACh use lost its significance. The ACh burden calculation was also found to 
be non-significant in determining discharge status. This could also possibly be due to 
many of the variables and response variables being significantly correlated with each other 
as per Table 13. Significant differences existed between those discharged to a community 
and those either discharged to an institution, other, or expired (p<.0001). There was also a 
significant difference between whether or not an individual experienced delirium and 
where they were discharged to (p<.0001). Those that did not experience delirium were 
more likely to be discharged to the community or expired compared to those that 
experienced delirium who were more likely to be discharged to either an institution or 
other. 
11. Limitations 
This study used data that was collected from large teaching hospitals, which may 
not reflect the prescribing patterns of community hospital doctors. 
Another limitation is in the ACh burden calculation by defining duration of therapy 
as either acute or chronic. The way acute (5 2 days) and chronic (>2 days) use was defined 
is arbitrary. From the data set it cannot be differentiated when the doses were given. For 
example, if someone received more than one dose and the days of therapy were less than 
their observed LOS, one cannot tell if those doses were given consecutively or if they were 
days apart. Another limitation of how the burden score was calculated is in summing the 
scores of each ACh drug received by a patient. The summing assumes that two drugs each 
with a rating of two would be equally ACh to one drug with a rating of 4. It is unknown if 
taking multiple ACh drugs if each drug's effect is additive or if there is a certain threshold 
and once that point is met the addition of anymore drugs will not exert any additional 
effect or if it could exert an exaggerated effect, the relationship could be synergistic. The 
calculation may have been more accurate if the dose was multiplied by atropine 
equivalents but that data was only available on four of the 3 1 drugs in the literature. 
Another limitation is the poorly documentation of delirium. Because it is a 
database study, it cannot be distinguished when the ACh drug was given in relation to 
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when the patient developed delirium. It is not possible to differentiate whether or not the 
ACh drug was used to treat delirium, such as the case with the use of many AP, or if it was 
causing the delirium. Also, because this is an observational study it cannot establish 
causation. 
111. Discussion: 
Use of cholinesterase inhibitors has been associated with an increased risk of 
receiving an ACh drug to manage urinary symptoms (Gill et a1 2005; Roe et al., 2002). 
Multiple studies have found that approximately 33% of those on ChEi are also receiving an 
ACh. Not only are those on ChEi at an increased risk (Gill et al., 2005) of being 
prescribed an ACh, it is common to find them on more than one ACh drug (Roe et al., 
2002). 
Medications have been implicated in at least 40% of delirium cases in hospitalized 
elderly patients (Francis et al., 1990). Time and time again, numerous studies have 
associated delirium with significantly increased adverse outcomes such as mortality, 
significantly increased LOS, institutionalization, and functional disability (Thomas et al., 
1988; Francis et a1 1990, 1992; Levkoff et al., 1992; Inouye et al., 1993; Murray et al., 
1993; Rockwood 1993), which are significant human and economic burdens. 
Carnahan et a1 found that nearly 75% of all ACh prescribed were inappropriate for 
use in the elderly and of those 22% were inappropriate under any circumstance (Carnahan 
et a1 2004). Another study by Agostini documented nearly 24% of all diphenhydramine 
doses given to hospitalized elderly patients as inappropriate (Agostini et al., 2005). 
Inappropriate use was defined as given as transfusion prophylaxis without prior 
documentation of having a previous reaction or given to individuals with obstructive 
urinary symptoms. In this study nearly 39% of all ACh drugs were given acutely and 32% 
of them given were diphenhydramine alone. 
There has only been one study conducted that looked at the prevalence of one ACh, 
diphenhydramine, use in hospitalized elderly patients, in one hospital and its effects on 
LOS and delirium. In that study, Agostini et al., found that the diphenhydramine exposed 
group was at an increased risk for delirium, urinary catheter placement, and longer median 
LOS. The dose-response relationship demonstrated a significant trend toward increased 
cognitive decline and delirium symptoms with increasing dose. 
The majority of studies that looked at the prevalence of concomitant use of ChEi 
therapy and ACh have been done with Medicaid administrative claims, which were 
performed before Medicaid Part D, may not be fully representative of this population. 
This study looked at billing data that was acquired from the UHC database which includes 
data from the 42 participating teaching hospitals. 
Thus far this is the first study to examine the ACh prevalence of more than one 
ACh drug (3 1 total), in hospitalized elderly dementia patients, diagnosed or inferred, that 
are or are not concurrently taking ChEi therapy. It is also the first to study the relationship 
between ACh use and burden in this population with adverse outcomes of longer 
hospitalization, development of delirium, and change in discharge status from community 
to an institution. 
What can be taken away from this study and added to the literature: ACh are 
commonly used in hospitalized elderly dementia patients in general (32.7%) and more 
specifically in those elderly dementia patients who are also concurrently taking ChEi 
therapy (35.9%). Those on a ChEi are more likely to receive an ACh. The most common 
ACh prescribed was for the treatment of urinary incontinence, a noted side effect of ChEi 
therapy. Oxybutynin and tolterodine were the two urinary antispasmodics that were 
frequently used in this population, accounting for nearly 11% of ACh use. The total 
number of ACh drugs and the ACh burden were significantly higher in elderly dementia 
patients on ChEi therapy. Of all ACh drugs given, 39% of them were given as one or two 
doses and 32% of them were diphenhydramine use, which usually means they were most 
likely given prophylactically and therefore does not need to be given. Diphenhydramine is 
routinely given for transfusion prophylaxis without a prior reaction documented. Also, the 
practice of administering diphenhydramine prophylactically without prior transfusion 
reaction has no documented benefit and should be avoided. 
ACh and ChEi drug use seem to be strongly correlated with each other. There is a 
significant difference in LOS between those who experience delirium and those that do not 
(p<.0001). There was also a significant difference on where one was discharged to 
depending on whether or not they experienced delirium (p<.0001). Those that did not 
experience delirium were more likely to be discharge to either community or expired and 
those that did experience delirium were more likely to be discharged to either an institution 
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or other. ChEi therapy seems to have an effect on whether a patient experiences delirium 
and where they are discharged to. 
There have been case reports of elderly individuals with a CNS compromisii~g 
condition treated with oxybutynin (MI selective) and tolterodine (non-selective 
antimuscarinc) developing hallucinations, confusion, and delirium. A preferred treatment 
option would be an agent that is M3 specific which have been shown to have no apparent 
impact on a wide variety of cognitive function tests or to try other methods first. A recent 
study showed that behavioural strategies (bladder retraining) assisted by biofeedback 
which has been shown to be more effective and acceptable than oxybutynin treatment in 
women with urge and mixed incontinence (Burgio et al., 1998). 
Behavioral and psychotic symptoms are very common among AD patients and 
have been reported in more than 80% of subjects in most studies. They are frequently 
treated with AP, mood stabilizers, and antidepressants (Mega et al., 1996; Stoppe et al., 
1999). TCA and AP like olanzapine should be avoided; AP with less ACh activity (e.g. 
risperidone) may be preferred in a population with dementia (Stoppe et al., 1999). 
In addition, cholinesterase inhibitor therapy is associated with significant cost for 
AD patients. ChEi and ACh drugs have opposing actions, and concomitant use of ACh 
drugs may therefore reduce the benefits of ChEi therapy. Giving other medications that 
block or counteract the potential benefits of this therapy make those costs an unnecessary 
burden on the family and the health care system as a whole. 
ACh use does not come without considerable cost to families and the health care 
system with its associated increased LOS, delirium, risk of being transferred to an 
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instituition, and mortality. Although some ACh use may be unavoidable in patients with 
dementia, alternatives with minimal or no ACh activity should be considered first. Careful 
consideration for potential adverse outcomes in a population that is already at high risk 
based on age, baseline cognitive impairment, and other medical comorbities needs to be 
taken into consideration when prescribing drugs for the treatment of some of the conditions 
that commonly accompany AD. 
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APPENDIX A 
Defining dementia patients 
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Senile degeneration of brain 
Presenile dementia with delirium 
Senile dementia with delirium 















































Specific Data Elements 
Total number of patients 
Number of patients taking 
AChic drug 
ChEi drug name, dosetday, 
days of therapy 




o AChic drug use 
(drug name, doselday, 
days of therapy) 
o ACh burden 
o Delirium? 
o Severity score 
o DIC toNH? 
o Admitted from? 
Stop 
NO 
Total number of dementia patients 
Stored UHC clinical 
data for most recent 
two quarters (total 
population 2 65) 
+ 
Dementia diagnosis or 
dementia drugs during 
hospitalization? 
Total number of dementia patients 
Number of patients taking AChic drug 
For each patient: 
o Age 
o Sex 
o Admitting diagnosis 
0 LOS 
o Delirium? 
o Severity score 
o D/C to NH? 
o Where admitted from? 
Number of patients taking AChic drug 
For each patient: 
o Age 
o Sex 
o Admitting diagnosis 
o LOS 
o Delirium? 
o Severity score 
o DIC toNH? 
Dementia patient g 4 ACh use I 









Total number of patients 
Number of patients taking 
AChic drug 
ChEi drug name, doselday, 
days of therapy 




o AChic drug use 
(drug name, doselday, 
days of therapy) 
o ACh burden 
o Delirium? 
o Severity score 
o DIC to NH? 
o Admitted from? 
Total number of patients 
Number of patients taking 
AChic drug 
ChEi drug name, doselday, 
days of therapy 




o AChic drug use 
(drug name, doselday, 
days of therapy) 
o ACh burden 
o Delirium? 
o Severity score 
o DIC to NH? 
o Admitted from? 
Total number of patients 
Number of patients taking 
AChic drug 
ChEi drug name, dosetday, 
days of therapy 




o AChic drug use 
(drug name, doselday, 
days of therapy) 
o ACh burden 
o Delirium? 
o Severity score 
o DIC toNH? 




11 = White 
2 = Black 
3 = Asian, Hispanic, Native American/Eskimo, unknown, other 
Admission Source 




Home Health referral 
CourtLaw enforcement 
HMO referral 
From Ambulatory surgery 
Routine 
2 = Institution 3= Other 
SNF (Skilled Nursing Facility) unknown 
Rehab center transfer 
Psych center newborn 
Alternative care facility 
Critical access hospital 
Intermediate care 
Short-term acute care 
Discharge status 
1= Community 2 = Institution 3 = Other 4 = Died 
Discharged Hospiclmed facility Transferred Expired 
Discharged home LTC hosp Other Expired autopsy 
Home w/HHC SNF Expired no autopsy 
Home wlIV Psych center 
Hospicelhome Rehab center 
1 Left AMA Federal hosp 
Other institution for outpatient ICF 
This institution for outpatien Acute care facility 
Primary Diagnosis (Based on ICD-9 codes) 
Blood d/o (280-289) DM (250-25 1) Respiratory diseaselinfection (460-5 19) 
Cancer (140-209) UTI (599) Respiratorylchest symptoms (786) 
Infection (001-139,440,785) Dementia (290-294,33 1) Gastrointestinal disease (520-579) 
Injury (830-957,990-995) Procedurelaftercare (V50-V59) Endocrine gland disorders (240-255) 
Genitourinary disease (580-629) Poisoning (960-979) Mentallmood d/o (290-3 19) 
Malnutrition (260-279, 783) Fracture (800-829) Electrolytelfluid imbalance (276) 
Muscularskeletal/connective tissue diseases (710-739) Skin/subcutaneous tissue disease (680-709) 
Symptomslunk causes of morbity & mortality (799) Circulatory/vascular/heart disease (390-459) 
SignsISymptoms of ill-defined conditions (780-799) Complications of medicallsurgical care (996-999) 
Other (V60-V85,210-229,320-324,742-75 1,790) 











































belladonna alkaloidslergotamine tartratelphenobarb 

























promethazine and combos I 
scopolamine (gastrointest) Img 
thioridazine Img 
tolterodine tartrate Img 
trihexyphenidyl I mg 
2= Medium; 3= High 
Dose 
1 I 2 1 3  
Potency 
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